 
  
Protocol I7H -MC-JNBA(b)  
 
 A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients 
with Advanced or Metastatic Cancer  
 
 [STUDY_ID_REMOVED]  
 
Approval Date: 28- Sep-2015 
I7H - MC- JNBA(b )  Phase  1  Onco logy  P ro toco l Page  1
LY31645301 .Pro toco l  I7H - MC- JNBA(b )
A  Phase  1  S tudy o f  LY3164530 ,  a  B ispec i f ic  An t ibody 
Ta rge t ing  MET  and  EGFR ,  in  Pa t ien ts  w i th  A dvanced  o r  
Me tas ta t ic  Cance r
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th is  p ro toco l  is  con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies  and  
shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lved  in  the  c l in ica l  inves t iga t ion  o f  
LY3164530 ,  a  b ispec i f ic  an t ibody  ta rge t ing  MET  and  EGFR,  un less  such  pe rsons  a re  
bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies.   Th is  
documen t  and  i ts  assoc ia ted  a t tachmen ts  a re  sub jec t  to  Un i tedS ta tes  F reedom  o f  
In f o rma t ion  Ac t  (FO IA )  Exemp t ion4 .
An t i- MET/ EGFRB ispec i f ic  An t ibody( LY3164530)
Th is  Phase  1  s tudy  is  a  mu l t icen te r ,  non random ized ,  open- labe l ,  dose - esca la t ion  s tudy  o f  
in t ravenous  LY 3164530in  pa t ien ts  w i th  advanced  o r  me tas ta t ic  cance r .
App ro va l  Da te :  28 -Sep -2015  GMTE l i  L i l l y  and  Compan y
Ind ianapo l i s ,  Ind iana  [LOCATION_003]  [ZIP_CODE]
P ro toco l  E lec t ron ica l lyS igned  and  App ro ved  b y  L i l ly02  Ap r i l  2014
Amendmen t  (a )  E lec t ron ica l ly  S igned  and  App roved  by  L i l ly  11  Augus t  2014
Amendmen t  (b )  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y  on  da te  p ro v ided  be low
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 2
LY31645302.Synopsis
This Phase 1 study  is a m ulticenter, nonrandomized, open -label, dose -escalat ion study  of 
intravenous LY3164530 in patients with advanced or metastatic cancer.
I7H - MC- JNBA(b )  Phase  1  Onco logy  P ro toco l Page  3
LY31645303 .Tab le  o f  Con ten ts
A  Phase  1  S tudy o f  LY3164530 ,  a  B ispec i f ic  An t ibody 
Ta rge t ing  MET  and  EGFR ,  in  Pa t ien ts  w i th  A dvanced  o r  
Me tas ta t ic  Cance r  
Sec t ion Page
CC I1 . P ro to co l I7H - MC- JNBA ( b )    A  P h a s e  1  S tudy  o f  LY3164530 ,  a  
B i s p e c i f i c  A n tibody  T a r g e t i n g  MET  a n d  EGFR ,  i n  P a t i e n t s  w i t h  
A dv a n c e d  o r  M e t a s t a t i c  C a n c e r. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2 . Syn o p s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
3 . T a b l e  o f  C o n t e nt s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
4 . A b b r e v i a ti o n s  a n d  D e f i n i ti o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
5 . I n t r o d u c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
5 .1 . R a t io n a l e  a n d  J u s t i f i c a ti o n  f o r  th e  S tudy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
5 .2 . O b j e c ti v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
5 . 2 . 1 . P r im a r y  O b j e c ti v e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
5 . 2 . 2 . S e cond a ry O b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
5 . 2 . 3 . Exp lo r a to ry  O b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
5 .3 . G e n e r a l  I n t r o d u c t i o n  t o  LY 3 1 6 4 5 3 0. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
5 . 3 . 1 . M e c h a n i sm  o f  A c ti o n  a n d  I n  V i t r o / I n  V i v o  A c t i v i ty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 6
5 . 3 . 4 . B iom a rk e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 8
5 .4 . R a t ion a l e  fo r  S e l e c t i o n  o f  D o s e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9
5 .5 . R a t ion a l e  fo r  Am endm en t  (b ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9
6 . I n v e s t i g a t i o n a l  P l an. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1
6 .1 . S tudy Popu l a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1
6 . 1 . 1 . I n c l u s i o n  C r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 1
6 . 1 . 2 . E x c l u s i on  C r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2
6 .2 . Summ a ry o f  S tudy  D e s ign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 3
6 . 2 . 1 . P r im a r y  E n d p oi n t  An a ly s i s ,  S tudy  Com p l e ti o n ,  a n d  E n d  o f  
T r ia l. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
6 .3 . D is con t inu a t i on s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 4
6 . 3 . 1 . D is con t inu a t i on  o f  P a t i en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
6 . 3 . 2 . D is con t inu a t i on  o f  S tudy  S i t e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5
6 . 3 . 3 . D is con t inu a t i on  o f  th e  S tudy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5
7 . T r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 4
LY31645307.1. Materi als and Supplies .................................................................................................26
7.2. Study  Drug Administration .......................................................................................... 26
7.2.1. Dosing Schedule .................................................................................................. 26
7.2.2. Dose Escal ation.................................................................................................... 26
[IP_ADDRESS]. Dose -Limit ing Toxicit y Determination ........................................................... 26
[IP_ADDRESS]. DLT -Equivalent Toxicit ies............................................................................. 27
[IP_ADDRESS]. Dose Escal ation Method ................................................................................. 27
7.2.3. Reco mmended Phase 2 Dose Determinat ion......................................................... 30
7.2.4. Moni toring and Treatm ent Gui dance for the Investigator ...................................... 30
[IP_ADDRESS]. Infusio n-Related Reactions ............................................................................. 30
[IP_ADDRESS]. Skin React ions................................................................................................ 31
7.2.5. Dose Delays and Adjustments .............................................................................. 31
[IP_ADDRESS]. Dose Delays and Omissio ns............................................................................ 31
[IP_ADDRESS]. Dose Adjustments ........................................................................................... [ADDRESS_418011] ion......................................................................................................................... 36
8.1. Safety Evaluat ions........................................................................................................ 36
8.1.1. Safety Data Collection and Review ...................................................................... 36
8.1.2. Adverse Events .................................................................................................... 36
[IP_ADDRESS]. Serious Adverse Events .................................................................................. 37
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting ..................................... 38
[IP_ADDRESS].1. Prior to Administrati on of  Study  Drug ...................................................... 38
[IP_ADDRESS].2. On Therapy ............................................................................................... 39
8.1.2. 2.3. Follow-Up Vi sit........................................................................................ 39
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 39
[IP_ADDRESS]. Summary  of AE/SAE Reporti ng Guidelines ................................................... 40
8.1.3. Other Safet y Measures ......................................................................................... 40
[IP_ADDRESS]. Electrocardiograms ......................................................................................... [ADDRESS_418012] ing..................................................................................... 42
8.2.1. Samples for Study  Qualificat ion and Healt h Monit oring ....................................... 42
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 5
LY31645308.2.2. Samples for Drug Concentration Measurements 
Pharmacokinet ics/Pharmacodynamics .................................................................. 42
[IP_ADDRESS]. Pharmacokinet ic Samples ............................................................................... 42
[IP_ADDRESS]. Pharmacodynamic Samples ............................................................................ 42
8.2.3. Samples for Tailoring Bio markers ........................................................................ 43
[IP_ADDRESS]. Tumor Ti ssue .................................................................................................43
[IP_ADDRESS]. Blood Sam ples for Pharm acogenetic Evaluat ions............................................ 44
[IP_ADDRESS]. Exploratory  Biomarker Bl ood Sam ples........................................................... 45
8.2.4. Samples for Immunogenicit y Research .................................................................45
8.3. Efficacy Evaluations .................................................................................................... 45
8.4. Procedure/Sampling Co mpliance .................................................................................. 46
9. Data Management Methods ............................................................................................... 47
9.1. Data Qualit y Assurance ................................................................................................ 47
9.2. Data Capture Systems .................................................................................................. 47
9.2.1. Case Report Form ................................................................................................ 47
9.2.2. Ancillary  Data ...................................................................................................... 47
10. Data Analyses ................................................................................................................... 49
10.1. General Considerations ................................................................................................ 49
10.2. Patient Disposi tion....................................................................................................... 49
10.3. Patient Characteri stics.................................................................................................. 49
10.4. Safety Analyses ............................................................................................................ 49
10.5. Pharmacokinet ic Analyses ............................................................................................ 50
10.6. Pharmacodynamic Analyses ......................................................................................... 50
10.7. Pharmacokinet ic/Pharmacodynamic Analyses .............................................................. [ADDRESS_418013] igator Informat ion....................................................................................... 53
11.3.2. Protocol  Signatures .............................................................................................. 53
11.3.3. Final Report Signature ......................................................................................... 53
12. References ........................................................................................................................ 54
I7H - MC- JNBA(b )  Phase  1  Onco logy  P ro toco l Page  6
LY3164530L is t  o f  Tab les
Tab le Page
CC I
T a b l e  JNBA . 3 . S amp l e  Do s e  E s c a l a t i o n  S c h em a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0
T a b l e  JNBA . 4 . D o s e  M o d i f i c a ti o n s  a n d  T r e a tm e n t  A l t e r a t i o n s  i n  P a t i e n t s  T r e a t e d  w i t h  
LY 3 1 6 4 5 3 0. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
T a b l e  JNBA . 5 . A dv e r s e  E v e n t  a n d  S e r i o u s  A d v e r s e  E v e n t  R e p o r t i n g  G u i d e l i n e s  f o r  
S tudy JNBA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
I7H-MC-JNBA (b) Phase [ADDRESS_418014] of Figures
Figure Page
Figure JNBA.1. Dose -finding spreadsheet of the modified toxicit y probabilit y interval  
method showing number of pat ients treated at a given dose vs. number 
of DLTs observed at that dose . ...................................................................... 29
I7H-MC-JNBA (b) Phase [ADDRESS_418015] ion Schedule ........ 68 Attachm ent 4.
Protocol  JNBA Hepat ic Monitoring Tests for Treatment -Emergent Attachm ent 5.
Abnorm ality.................................................................................................. 70
Protocol  JNBA Reco mmendat ions for Reporting Attachm ent 6.
SeriousAdverse Events ................................................................................. 71
Protocol  JNBA m TPI [INVESTIGATOR_338233]............................................................ 72 Attachm ent 7.
Protocol  JNBA Protocol  I7-MC-JNBA(b) Amendment Summary  A Attachm ent 8.
Phase 1 Study  of LY3164530, a Bispecific Antibody  Targeting MET 
and EGFR, in Pat ients with Advanced or Metastatic Cancer .......................... 74
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 9
LY31645304.Abbreviations and Definitions
Term Definition
ADA anti-drug antibody
AEAdverse event:  Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product that does not necessarily 
have a causal relationship with this treatment.  An adverse event (AE) can therefore 
be any  unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the us e of medicinal 
(investigational) product, w hether or not related to the medicinal (investigational) 
product.
ALT alanine aminotransferase
ANC absolute neutrophil count
ASCO American Society of Clinical Oncology
AST aspartate aminotransferase
AUC area under the serum concentration -time curve
AUC (0-tlast) area under the serum concentration -time curve from time zero to last measurable 
serum concentration
AUC (0-∞) area under the serum concentration -time curve from time zero to infinity
AUC 0-τ area under the serum versus time concentration -time curve over the dosing interval
audit A systematic and independent examination of the study -related activities and 
documents to determine whether the evaluated study -related activities were 
conducted, and the data were recorded, analyzed, and accurately reported according 
to the protocol, applicable standard operating procedures (SOPs), good clinical 
practice (GCP), and the applicable regulatory requirement(s).
Cav,τ average serum concentration over the dosing interval
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CL systemic clearance
Cmax maximum serum concentration
Cmin,τ minimum serum concentration over the dosing interval
CNS central nervous system
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 10
LY3164530complaintAny written, electronic, or oral communication that alleges deficiencies related to the 
identity, quality, purity, durability, reliability, safety, effectiveness, or performance 
of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
CRF/eCRF case report form/electronic case report form:  Sometimes referred to as clinical report 
form, a printed or electronic form for reco rding study  participants’ data during a 
clinical study, as required by [CONTACT_760].
CRP clinical research physician
CRS clinical research scientist
CSF colony-stimulating factor
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
D deescalate the dose
DLT dose-limiting toxicity
DNA deoxyribonucleic acid
DU deescalate the dose due to unacceptable toxicity
E escalate the dose
EC50 the half maximal effective serum concentration
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
EGFR epi[INVESTIGATOR_338234]/ECD epi[INVESTIGATOR_338235].
enroll Patients who are enrolled in the trial are those who have been assigned to a treatment 
and have received at least one dose of study treatment.  
enter Patients who are entered in the trial are those who have signed the informed consent 
form directly  or through their legally acceptable representatives.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 11
LY3164530ERB/IRB ethical review board/institutional review board:  /A board or committee (institutional, 
regio nal, or national) composed of medical and nonmedical members whose 
responsibility is to v erify that the safety, welfare, and human rights of the patients 
participating in a clinical study are protected.
FISH fluorescence in situ hybridization
GCP good clinical practice
HGF hepatocyte growth factor
HIV human immunodeficiency virus
ICF informed consent form
ICH International Conference on Harmonisation
IgG immunoglobulin G
IHC immunohistochemistry
IV intravenous
Informed 
consentA process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to 
participate in a particular trial, after having been informed of all aspects of the trial 
that are relevant to the patient’s decision to participate.  Informed consent is 
documented by [CONTACT_3553] a written, signed and dated informed consent form.
interim 
analysisAn analy sis of clinical study data that is conducted before the final database is 
autho rized for data lock .
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
Lilly Safety 
SystemGlobal safety database that tracks and reports serious adverse and spontaneous events 
occurring while using a drug/drug delivery system.
MedDRA Medical Dictionary for Regulatory Activities
MET mesenchy mal-epi[INVESTIGATOR_338236]/ECD mesenchy mal-epi[INVESTIGATOR_338237] A person responsible for ensuring the investigator site complies with the monitoring 
plan, applicable local SOPs (if any), and global Medical SOPs.  Monitors are trained
on the investigational product(s), the protocol, informed consent document, any other 
written information provided to subjects, relevant SOPs, International Conference on 
Harmonisation Good Clinical Practice guidelines (ICH -GCP), and all applicable laws 
(for example, privacy and data protection) and regulations.  
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 12
LY3164530MRI magnetic resonance imaging
mRNA microribonucleic acid
MTD maximum tolerated dose
mTPI [INVESTIGATOR_338238] -label A study  in which there are no restrictions on knowledge of treatment allocation, 
therefore the investigator and the study participants are aware of the drug therapy 
received during the study.
PD pharmacodynamic(s)
PK pharmacokinetic(s)
QTc corrected QT interval
Q2W once ever y [ADDRESS_418016] error
Sponsor The party who takes responsibility for the initiation, management ,and/or financing 
of a clinical study.
S[LOCATION_003]R suspected unexpected serious adverse reaction
t1/[ADDRESS_418017] upper limit of normal
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 13
LY3164530V volume of distribution
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 14
LY3164530A Phase 1 Study  of LY3164530, a Bispecific A ntibody  
Targeting MET and EGFR, in Patients with A dvanced or 
Metastatic Cancer
5.Introduction
5.1. Rationale and Justification for the Study
The epi[INVESTIGATOR_3506] (EGFR) and the m esenchymal -epi[INVESTIGATOR_338239] 
(MET) are receptor ty rosine kinases that each play a key  role in cancer signaling .  They  areco-
expressed in many tumors, and crosstal k between the signaling pathways controll ed by  [CONTACT_338264] a major mechanism for cancer progression and resistance to therapy .  
Mesenchymal -epi[INVESTIGATOR_338239] , also known as the hepatocy te growth factor (HGF) 
receptor, and its ligand HGF , have a significant r ole in tum or growth and m etastasi s.  Aberrant 
MET signaling has been implicated in the development of many  human cancers ,including 
breast, cholangiocarcino ma, col orectal , endo metrial, esophageal, head and neck, gastric ,renal, 
pancreat ic, bladder, liver, lung, prostate, melano ma, thy roid,and ovarian cancers (Ghera rdi et al .
2012).  Mesenchyma l-epi[INVESTIGATOR_338240] t from the 
overexpressio n of HGF or MET, activat ing mutations in MET, transact ivation, autocrine or 
paracrine signaling
, or MET gene amplification (Graveel et al.2013).  In addition, MET /HGF is
a critical player in developed resistance to targeted therapi[INVESTIGATOR_014], including therapi [INVESTIGATOR_338241] (Rem on et al . 2014) .  
Epi[INVESTIGATOR_338242] a crucial ro le in tumor biology by [CONTACT_338265], angiogenesis, metastasis ,and survival o f cancer cell s.  Therapi[INVESTIGATOR_338243]-small cell lung, col orectal , pancreat ic, and hea d and neck 
cancers.  Multiple mechanisms of resistance to EGFR -targeted therapi [INVESTIGATOR_338244],
and include mutations in EGFR and downstream proteins such as KRAS, histologic 
transformation, and the act ivation of alternat ive pathways ,including the MET si gnaling pathway  
(Chong andJanne 2013) .  
Co-expressio n and act ivation of MET and EGFR are found in a number of tumor types,
including non-small cell lung , 
colorectal , gastric, and head and neck cancers (Scheving et al .
2002; Bonine -Summers et al .2007; Nanjo et al. 2013).  Blocking one receptor tends to up -
regul ate the other, l eading to resi stance to single- agent treatm ent(Engelman et al. 2007) .  
Amplification o f MET and/or high levels o f HGF expressio n has been observed in non-small cell 
lung ca ncer patients with intrinsic or acquired resistance to tyrosine kinase inhibitors of EGFR, 
including erlotinib and gefit inib (Engelman et al. 2007 ;Yano et al . 2011).   Conversely, MET -
amplified l ung cancer cells exposed to MET -inhibiting agents for a prolonged period develop 
resistance via the EGFR pathway  (McDerm ott et al . 2010) .  
The crosstalk between the MET and EGFR pathways suggests that dual inhibit ion of these 
targets m ay lead to improved outcomes for patients with an MET- and EGFR -positive cancer ,
I7H-MC-JNBA (b) Phase [ADDRESS_418018] .
Unlike early versio ns of bispecific ant ibodies ,which simply  aimed at crossli nking receptors on 
the surface of immune cells, LY316453 0 is an engineered bispecific antibody  designed to 
neutralize , internalize ,and disrupt signaling via both the MET and EGFR receptors.  It consists 
of an immunoglobulin G (Ig G)4 antibody  to MET and a single -chain variable fragment (scFv) to 
EGFR fused to the N -terminus of each heavy chain.  LY3164530 consists of 2 ident ical heavy 
chains and 2 ident ical light chains.  
This bispecific ant ibody  may offer an advantage over combining 2 different ant ibodies since , as 
described below (Secti on 5.3) and in the Invest igator’s Brochure, the dual  inhibition may lead to 
more efficient internalizat ion and subsequent degradation of both the MET and EGFR receptors.  
The init ial Phase 1 study  with LY3164530, Study  I7H-MC-JNBA (JNBA), will characteri ze the 
safet y and determine the recommended Phase 2 dose (RP2D) of LY3164530 in patients with 
advanced or metastatic cancer.
The Sponsor , monitor, and investigators will perform this study in co mpliance wit h the protocol, 
good clinical pract ice (GCP) and Internat ional Conference on Harmonisat ion (ICH) guidelines, 
and applicable regulatory  requi rements.
5.2. Objectives
5.2.1. Primary Objective
The primary  object ive of this study  is to determine a nRP2D and schedule of LY3164530 that 
may be safely  administered to pati ents wi th advanced or metastati c cancer .
5.2.2. Secondary Objectives
The secondary  objectives of this study  are:
to characterize the safet y and toxi city profile of LY 3164530
to estimate the pharmacokinet ic (PK) parameters of LY 3164530
to document any  antitumor activit y observed wit h LY 3164530.
5.2.3. Exploratory Objectives
The e xploratory  objectives of this study  are:
to explore the effect of LY3164530 on pharmacodynamic (PD) markers 
to identify exploratory  biomarkers associ ated wi th tumorresponse and /or 
safet y.  
5.3. General Introduction to LY3164530
LY3164530 is an engineered bispecific ant ibody  targeting MET and EGFR , 
derived fro m a MET 
antibody  (LY2875358) and humanized cetuximab, an EGFR antibody .  During Phase 1 dose 
I7H - MC- JNBA(b )  Phase  1  Onco logy  P ro toco l Page  16
LY3164530e s c a l a t i o n ,LY 2 8 7 5 3 5 8  h a s  b e e n  w e l l  t o l e r a t e d .   N o  d o s e - l im i t i n g  t o x i c i t i e s  ( DLT s) ,  s e r i o u s  
adv e r s e  ev en t s  ( SAE s) ,  o r  ≥G r a d e  3  a d v e r s e  e v e n t s  (AE s)po s s ib ly  r e l a t ed  to  LY2875358  w e r e  
r e p o r t e d  a t  d o s e s  u p  t o  2 0 0 0  m g  a dm i n i s t e r e d  e v e r y  2  w e e k s .  Th e  mo s t  f r equ en t  AE s  po s s ib ly  
r e l a t ed  to  LY2875358  w e r e  n au s e a  (8 .7% ) ,  vom i t i ng  (8 .7% ) ,  and  d i a r rh e a  (8 .7% )  (Go l dm an  e t  a l .
2 0 1 3 ) .   T h e  t o x i c i ti e s  o f  c e t u x im a b  h a v e  b e e n  w e l l  c h a r a c t e r i z e d ,  a n d  i n c l u d e  c u t a n e o u s  AEs  
( r a s h ,  p ru r i tu s ,  a n d  n a i l  c h a n g e s ),  d i a r r h e a ,a n d  i n f u s i o n - r e l a t edr e a c t i on s .   I t  i s  exp e c t ed  th a t  
LY 3 1 6 4 5 3 0  w i l l  h a v e  a  t o x i c i ty  p r o f i l e  c o n s i s t e n t  w i t h  t h e s e  a g e n ts .   
M o r e  i n f o rm a ti o n  a b o u t  t h e  k n ow n  a n d  e x p e c t e d  b e n e f i t s ,  r i s k s ,a n d  r e a s o n a b l y  a n t i c i p a t e d  AE s  
m a y  b e  f o u n d  i n  t h e  I n v e s t i g a t o r ’ s  B r o c h u r e .   I n f o rm a ti o n  o n  AE s  e x p e c t e d  t o  b e  r e l a t e d  t o  t h e  
i n v e s t i g a t i o n a l  p rodu c tm ay  b e  f o u n d  i n  S e c ti o n  7  (D e v e l o pm en t C o r e  S a f e t y  In fo rm a t i o n )  o f  t h e  
I n v e s t i g a t o r ’ s  B r o c h u r e .   In fo rm a t i o n  o n  SAE s  e x p e c t e d  i n  t h e  s t u d y  p o p u l a ti o n  i n d e p e n d e n t  o f  
d r u g  e x p o s u r e  a n d  t h a t  w i l l  b e  a s s e s s e d  b y  t h e  S p o n s o ri n  a g g r e g a t e ,  p e r i o d i c a l l y  d u r i n g  t h e  
cou r s e  o f  th e  s tudy ,  m a y  b e  f o u n d  i n  S e c t i o n  6  (E f f e c t s  i n  H um a n s )  o f  t h e  I n v e s t i g a t o r ’ s  
B r o c h u r e.
5 .3 .1 .Mechan ism  o f  Ac t ion  and  In  V i t ro / In  V ivo  Ac t iv i ty
CC ILY 3 1 6 4 5 3 0  h a s  h i g h  a f f i n i ty  f o r  b o t h  MET  a n d  EGFR  a n d  b i n d s  b o t h  r e c e p t o r s  s im u l t a n e o u s l y
in  tum o r  c e l l s .   A s  d e s c r i b e d  i n  t h e  I n v e s t i g a t o r ’ sB r o c h u r e(S e c t i o n  5 .2 .2 ) ,  b i n d i n g  o f  
LY 3 1 6 4 5 3 0  t o  MET  a n d  EGFR  b l o c k s  a c ti v a t i o n  o f  b o t h  r e c e p t o r s  b y  th e i r  r e s p e c t i v e  l i g a n d s .   
I n  a d d i t i o n  to  i t s  l i g a n d - b l o c k i n g  a c ti v i t y , LY3164530  a ls o  l e a d s  t o  i n t e r n a l i z a t i o n  a n d  
d e g r a d a t i o n  o f  b o t h  r e c e p t o r s  i n  tum o r  c e l l s .   T h e  a b i l i ty  o f  LY 3 1 6 4 5 3 0  t o  i n t e r n a l i z e  b o t h  
r e c ep to r s  i s  s u p e r i o r  t o  t h e  c om b i n a t i o n  o f  i n d i v i d u a l  m o n o c l o n a la n ti b o d i e s .   T h e  i n t e r n a l i z a t i o n  
o f  bo th  r e c ep to r s  i s  m os t  c omm o n lyo b s e r v e d  i n  c e l l s  e x p r e s s i n g  h i g h  l e v e l s  o f  MET .   I n  
add i t i on ,  LY 3 1 6 4 5 3 0  a l s o  i n c r e a s e s  t h e  a v i d i ty  b i n d i n g  t o  MET  i n  c e l l s  e x p r e s s i n g  b o t h  MET  
a n d  EGFR ,  l e a d i n g  t o  b e t t e r  n e u t r a l i z a t i o no f  HGF  com p a r e d  t o  t h e  p a r e n t a l  MET  a n ti b o d y  
a l o n e  o r  i n  c om b i n a ti o n  w i th  c e t u x im a b .   Th e  ab i l i ty o f  LY3164530  to  b l o ck  l ig and - r e c e p to r  
i n t e r a c t i o n sa n de f f i c i e n t l y  i n t e r n a l i z e  MET  a n d  EGFR ,a n d  i t s  i n c r e a s e d  a v i d i t y  f o r  MET ,i s  
b e l i e v e d  t o  b e  r e s p o n s i b l e  f o r  t h e  i n  v i t r o  a n t i p r o l i f e r a t i v e  a c ti v i t y  o b s e r v e d  a g a i n s t  a  p a n e l  of  
tum o r  c e l l  l i n e s .   I n  v i v o ,  a dm i n i s t r a t i o n  o f  LY 3 1 6 4 5 3 0  r e s ul t s  i n  d o s e - d ep end en t  an t i tumo r  
a c t i v i t y  i n  c e l l  l in e - d e r i v e d  n o n -sm a l l  c e l l  l u n g  c a n c e r ,g a s t r i cc an c e r ,a n d  s q u am o u s  c e l l  c a n c e r  
o f  t h e  h e a d  a n d  n e c k  ( SCCHN)x e n o g r a f t s ,a s  w e l l  a s  i n  co l o r e c t a l  c a n c e r  a n d  SCCHN  p a t i e n t-
d e r i v e d  x e n o g r a f t s .   
I7H - MC- JNBA(b )  Phase  1  Onco logy  P ro toco l Page  17
LY3164530CC I
I7H - MC- JNBA(b )  Phase  1  Onco logy  P ro toco l Page  18
LY31645305 .3 .4 .B ioma rke rsCC I
I n  o r d e r  t o  a s s e s s  th e  c a p a c i t y  o f  LY3164530  to  inh ib i t  th e  MET  and  EGFR  p a thw ay s ,  p r e -a n d  
p o s t- t r e a tm e n t  a s s e s sm e n t s  o f  c i r c u l a t i n g  b i om a r k e r s  i n c l u d i n g ,  b u t  n o t  l im i t e d  t o , th e  MET  
l i g a n d  ( HGF) ,  EGFR  l i g a n d s  ( e g ,EGF ,  t r a n s f o rm i n g  g r ow t h  f a c t o r  [ TGF] - a l p h a ) ,  MET  
e x t r a c e l l u l a r  d om a i n  (MET /ECD ) ,  a n d  EGFR  e x t r a c e l l u l a r  d om a i n  (EGFR /ECD )m a y  b e  
an a ly z ed .   
M e s e n c h ym a l- ep i th e l i a l  t r an s i t i on  f a c to rp r o t e i n  e x p r e s s i on  i n  t um o r s  h a s  b e e n  l i n k e d  t o  c l i n i c a l  
ou t com e s  to  MET  th e r apy  ( M a r t e n s  e t  a l .  2 0 0 6 ;  J i n  e t  a l .  2 0 0 8 ,  Sp i g e l  e t  a l .  2 0 1 3 ) .   T h e r e f o r e,
p r e - t r e a tm en t  tum o r  b i op sy  t i s s u e  shou l d  b e  ob t a in eda n d  p r i o r  a r c h i v e d  t i s s u e  w i l l  b e  r e q u e s t e d
i n  o r d e r  t o  r e t r o s p e c t i v e l y  a s s e s s  po t en t i a l  m a rk e r s  a s so c i a t ed  w i th  r e s p on s e .   H ow e v e r ,  f o r  
p a t i e n t s  w h o  h a v e  d i s e a s e  r e cu r r en c e /m e t a s t a s i s  i n  t e c h n i c a l l y  ch a l l eng ing  s i t e s  to  ob t a in  
b i o p s i e s  o r  w h o  h a v e  ti s s u e  a v a i l a b l e  f r om  a  p r i o r  p o s t - t r e a tm en t  b i op sy  a n d  h a v e  n o t  r e c e i v e d  
i n t e rv en ing  th e r apy ,  t h e  i n v e s t i g a t o r  a n d  S p o n s o r  m a y  a g r e e  t o  om i t  t h e  p r e t r e a tm e n t  b i o p s y .   In
a r c h i v e d  a n d  p r e - t r e a tm en t  t i s su e  s amp l e s ,  an a ly t e s  r e l a t e d  t o  t h e  MET  a n d  EGFR  p a t hw a y s  a n d  
c a n c e r  p a t h o b i o l o gy  i n c l u d i n g ,  b u t  n o t  l im i t e d  t o,METa n dEGFR  p r o t e i n  e x p r e s s i on  m ay  b e  
e v a l u a t e d .   I n  t um o r  t i s s u e  a n d  c i r c u l a t i n g  d eoxy r ibonu c l e i c  a c id  ( DNA) ,s om a t i c  m u t a t i on  s t a tu s  
and /o r  copy  n um b e r  v a r i a ti o n s  o f  MET  a n d  EGFR  p a t hw a y - r e l a t e d  g e n e s  ( e g ,KRAS ,  BRAF )  o r  
g e n e s  r e l a t e d  t o  c a n c e r  p a t h o b i ol o gy  m ay  b e  a s s e s s ed .   I n  a d d i t i o n ,  tum o r  s am p l e s  m ay  b e  
e v a l u a t e d  f o r  p o t e n t i a l  t um o r  g e n e  s i g n a t u r e ( s ) ,  p o t e n t i a l ly  em p l oy ing  t a rg e t ed  o r  h i gh -
th r o u g h p u t  s e q u e n c i n g  a p p r o a c h e s .   
A  b lood  s am p l e  w i l l  b e  s to r ed  to  s tudy  g e n e t i c  v a r i a n t s  i n  d r u g  m e t a b ol i sm  a n d  t r a n s p o r t ,  t o  
m e a su r e  le v e l s  o f  t a rg e t  p a thw ay  p r o t e i n s ,  o r  f o r  g e n e t i c  a n a l y s i s  o f  p a thw ay - r e l a t ed  m a rk e r so f  
e i th e r  r e spon s e  o r  tox i c i ty ,  i f  d e em ed  n e c e s s a ry  by  [CONTACT_3433] e  Spon so r .
I7H - MC- JNBA(b )  Phase  1  Onco logy  P ro toco l Page  19
LY31645305 .4 .Ra t iona le  fo r  Se lec t ion  o f  Dose
A  f i x e d  s t a r t i n g  d o s e  o f  3 0 0  m g  LY 3 1 6 4 5 3 0  a dm i n i s t e r e dIV  o n c e  e v e r y  2  w e ek s  w a s  s e l e c t ed  
b a s e d  o n  d a t a  f rom  non c l in i c a l  tox i c o l o gy  s t u d i e s  a n d  m od e l ing  o fPK /PD  d a t a  f r om  n o n c l i n i c a l  
s tud i e s  o f  LY3164530 .   
 
Thes t a r t i n g  d o s e  i s  s i g n i f i c a n t l y  l o w e r  t h a n  t h e  
c o r r e s p o n d i n g  w e e k l y  do s e  o f  c e tux im ab b a s e d  o n  body  su r f a c e  a r e a .    
 
 
 
 
S e e  S e c t ion  5o f  th e  
LY 3 1 6 4 5 3 0  I n v e s t i g a t o r ’ s  B r o c h u r ef o r  add i t i on a l  d e t a i l s .
I n  a d d i t i o n ,  as t a r t i n g  d o s e  o f  3 0 0m gi sp r ed i c t ed  to  b e  i n  a  r a n g e  t o  a c h i e v e  b i o l o g i c a l  e f f e c t s  i n  
hum an s .   
 
T h e  PK /PD  
r e l a t i o n s h i p  ( e g ,  t h e  m o d e l  s t r u c t u r ea n d  m a x im a l  e f f e c t )  o b s e r v e d  i n  MKN 4 5  x e n o g r a f t  m o d e l s  
w a s  a s s um e d  t o  t r a n s l a t e  d i r e c tl y  t o  p a t i e n t s  w i t h  c a n c e r .A s  a  r e s u l t ,  wh e na dm i n i s t e r e d  IV
e v e r y2w e e k s ,  LY 3 1 6 4 5 3 0  d o s e s  g r e a t e r  t h a n  1 0 0  m g  a r e  p r e d i c t e d  t o  a c h i e v e  b i o l o g i c a l  e f f e c t s  
i n  h um a n s .S i n c e  w e i g h t- b a s e d  d o s i n g  o f  m ono c l on a l  an ti b o d i e s  h a s  n o t  b e e n  c o r r e l a t e d  w i t h  a  
r edu c t i o n  i n  PK  o r  PD  v a r i a b i l i ty ,  a  f i x e d - do s e  s t r a t egy  w a s  c h o s e n  b e c a u s e  i t  m i n im i z e s  t h e  
po t en t i a l  f o r  do s ing  e r ro r s  in  th e  c l in i c ,  e l im i n a t e s  t h e  n e e d  f o r  c om p l e x  d o s i n g  a l g o r i t hm s  b a s e d  
on  body  s i z e ,  a n d  i s  c o n s i d e r e d  t o  b e  s a f e  (W a n g  e t  a l .  2 0 0 9 ) .   
B a s e d  o n  t h e  d a t a  f r om  n o n c l i n i c a l  t o x i c ol o gy  s t u d i e s  a n d  m o d e l i n g  o f  PK /PD  d a t a , th e  s t a r t i n g  
d o s e  o f  LY 3 1 6 4 5 3 0  i n  S t u d y  JNBA  w i l l  b e  300  mg  adm in i s t e r ed  IV  on c e  ev e ry2  w e e k s.
5 .5 .Ra t iona le  fo r  Amendmen t  (b )CC I
A s  o f  2 7Ju l y2 0 1 5 ,  15  p a t i e n t s  h a v e  b e e n  t r e a t edi n  S t u d y  JNBA  a t  d o s e s  o f  3 0 0 ,  6 0 0 ,  1 0 0 0 ,  a n d  
1 2 5 0  m g  o n  D a y s  1  a n d  1 5  o f  a  2 8  d ay  c y c l e .   O n e  DLT  (C y c l e  1 )  h a s  b e e n  r e p o r t e d  i n  a  p a t i e n t  
a t  t h e  1 0 0 0  m g  d o s e  l e v e l  w h o  e x p e r i e n c e d  i n t o l e r a b l e ,G r a d e  2  r a s h .   Tw o  o f  t h e  3p a t i en t s  
t r e a t ed  a t  th e  1 2 5 0  m g  do s e  l ev e l  exp e r i e n c e d  AE s  i n  C y c l e  2  t h a t  w o u l d  h a v e  m e t  t h e  c r i t e r i a  f o r  
a  DLT  h ad  th ey  o c cu r r ed  in  Cy c l e  1  (DLT - e q u i v a l e n t  t o x i c i t y ).   T h e s e  e v e n t s  i n c l u d e d  G r a d e  3  
pu s tu l a r  r a sh  in  on e  p a t i en t  and  G r ad e  3  d e rm a t i t i s  a c n e i f o rm  a n d  G r a d e  4  h y p o m a gn e s a em i a  i n  
ano th e r  p a t i en t .   A s  a  r e s u l t ,  a  d o s e  o f  1 2 5 0  m g  w a s  d e em e d  t o  e x c e e d  t h em ax imum  to l e r a t ed  
do s e .   A s  o f  27  J u l y  2 0 1 5 ,  6  p a t i e n t s  h a v e  b e e n  t r e a t e d  a t  th e  1 0 0 0m g  do s e  l e v e l  a n d  e n r o l lm e n t  
w i l l  c o n ti n u e  u n t i l  1 0 - 20  p a t i en t s  h av e  b e en  t r e a t eda t  t h e  r e c omm e n d e d  P h a s e  2do s e .  
T h e  d r u g- r e l a t e d ,  t r e a tm e n t  em e r g e n t  a d v e r s e  e v e n t s  r e p o r t e d  f o r  LY 3 1 6 4 5 3 0  a r e  c o n s i s t e n t  w i t h  
i n h i b i t i o n  of  EGFR  a n d  i n c l u d e  s k i n  r e a c t i o n s[m a cu l o -p apu l a r  r a sh ,  d e rm a t i t i s  a c n e i fo rm ,  s k i n  
f i s s u r e s ,  r a s h ,  s k i n  e x f o l i a t i o n ,and /o r  pu s tu l a r  r a sh ]  (n=14 ,  9 3 . 3% ) ,  h y pom a g n e s a em i a  ( n= 7 ,  CC I
CC I
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 20
LY316453046.7%), and parony chia (n=4, 26.7%).  The following drug -related events occurred in 2 patients 
each (13.3%):  decreased appetite, dysgeuesia, fat igue, and hypokalaemia .  One SAE 
(hypo magnesaemia) was considered to be related to LY3164530 by  [CONTACT_338266].  The event occurred in a metastatic cutaneous squamous cell carcino ma pat ient who 
had Grade [ADDRESS_418019] 1 dose of LY 3164530 administered as a 1or 2-hour infusio nonce every 2
weeks (Q2W) across the dose range of 300-
1250 mg .Dose-dependent increases in the systemic 
exposure (AUC, C max)of LY3164530 fo llowing single and m ultiple doses were observed . A 
minor am ount of accumulat ion in serum wasobserved wit hin Cycle 1 and between Cycles 1 and 
2of treatment after 1000 mg Q2W (mean accumulation ratio of 1.1within and between cycles ). 
The LY3164530 systemic clearance (CL) decreased by [CONTACT_3450]  2-fold on average when 
the dose wa s escalated from 600 m g to 1000 m g, indicat ing the saturation of cell -surface 
receptors by [CONTACT_36940]3164530 and a slower non -receptor -mediated cl earance predominat ing at doses 
>600 m g.  While a more rapid receptor -mediated clearance (ie, target mediated drug disposit ion
[TMDD ]) predominates at low doses (i e, ≤60
0 mg).  In add ition, the LY3164530 exposure 
following 1000 m g Q2W appe ars to be in an exposure range expected to achieve bio logical  
effects based on the nonclinical MKN45 xenograft PK/PD model est imates for the MET and 
EGFR half maximal effect ive serum concentrations ( EC 50) values .  The LY3164530 maximum 
serum concentrati on (Cmax) after 1000 m g in Cycles 1 and 2 is greater (mean C max range: 29 5-394 
µg/m L) than both the MET EC 50 (79.5 µg/m L; 0.4 µM ) and EGFR EC 50(7.95 µg/m L; 0.04 µM ) 
concentrations. T heaverage LY3164530 serum concentrati on over the d osing inter val (C av,τ)
during C ycles 1 and 2 isalsogreater (mean C av,τ range: 102 -
132µg/m L)than the MET EC 50 and 
EGFR EC 50.  
However, the minimum serum concentrati onover the dosing interval (Cmin,τ) of 
LY3164530 fo llowing 1000 mg in Cycles1 and 2 ( mean Cmin,τrange : 19-49 µg/m L)is lower
than the MET EC 50(79.5 ug/mL), which is the desired concentration to maintain throughout the 
dosing interval in order to maximize the biological activit y of LY3164530
.
At a dose of 1000 m g, the m ean terminal  eliminat ion-life(t1/2) is approximate ly 100 hours 
(approximately 4 days) .  As a resul t, the administration of LY3164530 every 2 week smay not be 
the optimal schedule of administration in order to achieve aLY3164530 Cmin,τnear the MET 
EC 50.  Therefore , it is hypothesi zedthat weekly  dosing of LY3164530 (ie, Days 1, 8, 15, and 22 
of a 28 day  cycle) willminimize the fluctuation between the peak (C max)andtrough (C min,τ)
serum  concentrati onsof LY3164530 leading to a more consistent inhibit ion of both MET and 
EGFR over the dosing interval (with minimal impact on the accumulat ion of LY3164530) and 
potenti ally greater pharmaco logic activit y (PD response ).  TheMTD of LY3164530 when 
administered on Days 1 and 15 of a 28 day  cycle is 1000 mg.  As a result, the starting dose for 
the weekly sche dule will  be 500 m g.  The safet y, toxicity, PK, and PD associated with a weekly 
schedule will be assessed.  
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 21
LY31645306.Investigational Plan
6.1. Study Population
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be re -
screened.   Each time re -screening is performed, the individual must sign a new informed consent 
form (ICF) and will be assigned a new ident ificat ion number.   
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol waivers or exempt ions, are not permitted.
6.1.1. Inclusion Criteria
Patients m ay be included in the study  if they  meet all  of the f ollowing cri teria during screening 
prior to fi rst dose of study  drug.
[1] Have histological or cy tological evidence of a diagnosis of cancer that i s 
advanced and/or metastatic.  The patient must be, in the judgment of the 
investigator, an appropriate candidate for experimental therapy (eg,available 
standard therapi[INVESTIGATOR_338245], the patient is not elig ible for standard 
curative therapy, or the patient has refused standard therapi[INVESTIGATOR_014]).  
[2] Have the presence o f measurable and/or nonm easurable disease as defined by  
[CONTACT_338267] (RECIST ) version 1.1
(Eisenhauer et al. 2009).
[3] Are 18 years of age.
[4] Have given written informed consent prior to any  study -specific procedures .
[5] Have adequate organ funct ion, including:
Hem atologic:  Absol ute neutrophil count (ANC) 1.5x 10 9cells /L, 
platelets 100 x 10 9/L, and hemoglobin 8g/dL .  
Transfusio ns to meet 
enrollment criteria are not allowed in the [ADDRESS_418020] dose 
of study  drug .  
Hepati c:  Bilirubin 1.5 times upper limit s of normal  (ULN), al anine 
amino trans ferase (ALT), and aspartate amino trans ferase (AST) 3times 
ULN.  If the liver has tumor invo lvement, AST and ALT equaling 
5times ULN are acceptable.
Renal:  Serum creat inine 1.[ADDRESS_418021].
[6] Have a performance status of 1 on the Eastern Cooperative Onco logy Group 
(ECOG) scal e.
[7] Prior Treatm ents
Systemic treatments :  Have discont inued previous systemic treatments 
for cancer and recovered from the acute effects of therapy.  Prior to first 
dose of study  treatm ent, pati ents m ust have discontinued:
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 22
LY3164530Cytotoxi c therapi[INVESTIGATOR_338246] [ADDRESS_418022] 28 days (whichever is shorter) .  
Mitomycin -C or ni trosourea therapy  for at l east 42 day s.
Biologic agents (eg ,antibodies) for at least 28 days .
At the di screti on of  the invest igator, hormone -sensi tive prostate 
cancer pati ents receiving gonadotropin releasing hormone agonist 
therapy  and breast cancer patients on antiestrogen therapy ( eg, an 
arom atase inhibitor) may  have that treatm ent continued while they  
are enrolled in Study  JNBA .  However, the treatment should ha ve 
been started at least [ADDRESS_418023] dose of study  drug.
Radiation therapy:  Limited field therapy must be completed [ADDRESS_418024] dose of study  treatm ent.
Major surgery (excluding biopsy):   Must be completed at least 4weeks 
prior to fi rst dose of study  treatm ent and patient must have recovered from 
the acute effects of the surgery .
[8] Are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures.
[9] Men and w omen with reproductive potential:  Must agree to use a reliable 
method of birth control during the study  and for [ADDRESS_418025] 
dose of study  drug or coun try requi rements, whichever is longer.
[10] Females with childbearing potential:  Must h ave had a negat ive serum 
pregnancy test ≤[ADDRESS_418026] feeding.
6.1.2. Exclusion Criteria
Potenti al study  patients m ay not be included in the study  if any of the fo llowing apply during 
screening.
[11] Have received treatment within [ADDRESS_418027] or non -approved use of a drug or device (other than 
the study  drug/device used in this study )for non -cancer indicat ionsor are 
concurrent ly enro lled in any other ty pe of m edical  research j udged not to be 
scientifically or medically co mpatible wit h this study .
[12] Have serious preexist ing medical condit ions or conco mitant disorders that ,in 
the opi [INVESTIGATOR_35272] ,would exclude the patient as a candidate for 
this study .
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 23
LY3164530[13] Have act ive centr al nervous system  (CNS) or l eptomeningeal metastasis 
(brain metastasis) at the time o f study  entry .  Patients with a history  of a CNS 
metastasis previously treated with curative intent (eg, stereotactic radiat ion or 
surgery ) that have not progressed on fo llow-up imaging, have been 
asymptomat ic for at least 28 days and are not receiving corticosteroids and 
or/anti convulsants, are eligible .  Patients with signs or symptoms of 
neuro logical com promise shoul d have appropri ate radi ographic imaging 
perform ed befor e study  entry  to rul e out brain m etastasis.  
[14] Have current acute or chronic leukemia .
[15] Have an act ive symptom atic fungal, bacterial, and/or known viral infect ion 
including human immunodeficiency  virus (HIV)or viral (A, B, or C) hepatit is 
(screening is not required) .  
[16] Have a second primary malignancy that ,in the judgment of the investigator or 
Sponsor ,may affect the interpretation of results.
[17] Have Bazett’s corrected QT interval ( QTc)of >470msec on screening 
electrocardi ogram  (ECG )in repeated measurements .
Note :  Patients with permanent pacemakers may enter study  if QTc is 
>[ADDRESS_418028] ion and not an intrinsic (non -
paced beat) conduction .  
[18] Have a serious cardiac condit ion, such as congestive heart fail ure; [LOCATION_001] 
Heart Associ ation Class III/IV heart disease; unstable angina pectoris; 
myocardial  infarct ion within the l ast 3 m onths; valvulopathy  that i s severe, 
moderate, or deemed clinically significant; or arrhy thmias that are 
symptom atic or require tr eatm ent (not including patients with rate -controlled 
atrial fibrillat ion).
[19] Have a known allergy /history  of hypersensit ivityto any  of the study  drug 
components, or to m onocl onal ant ibodies or other therapeut ic proteins such as 
fresh frozen plasma, human se rum albumin, cy tokines, or interleukins .
6.2. Summary of Study Design
Study  JNBA is a m ulticenter, nonrandomized, open label, dose escalat ion Phase 1 study  of IV 
LY3164530 in patients with advanced and/or metastatic cancer. Eligible pat ients will receive 
LY316 4530 as an infusio n on Days 1 and 15 (Sche dule 1) or on Day s 1, 8, 15, and 22 (Schedule 
2) of each cycle .  A cy cle will  consist of 28 days and the schedules will enro ll in parallel . 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 24
LY3164530Dose escalat ion will be driven by  a modified toxi city probabilit y interval  (mTPI) method.  The 
RP2D and schedule will be determined once at l east 10 patients , but no m ore than 2 0,are treated 
at a dose and schedule that is at or below the maximum tol erated dose ( MTD ).  The actual 
sample size for Study JNBA is ant icipated to be approximately  [ADDRESS_418029] been fulfilled (Section 6.3.1 ).  
6.2.1. Primary Endpoint Analysis, Study Completion ,and End of Trial
The primary  endpoint analysis will occur after the final pat ient enrolled has been evaluated for at 
least [ADDRESS_418030] 1 cycle of treatment or 
discontinued due to an AE(during Cycle 1) ,and completed the required post-treatm ent safet y 
assessment ,will be considered to have completed the study .  
However, addit ional cycles of 
therapy  may cont inue as lo ng as the patient is receiving benefit and no cri teria for 
discontinuat ion have been met. All secondary/exploratory  endpoint analyses will be updated at 
study  com pletion.
Both t he study completion and end o f trialwill be the date of the l ast vi sit or l ast schedule d 
procedure for the last patient.
6.3. Discontinuations
6.3.1. Discontinuation of Patients
The cri teria for enrollment must be fo llowed explici tly. If a pati ent who di d not m eet enrollment 
criteria and was inadvertent ly enro lled is ident ified, either by [CONTACT_338268], a 
discussio n must occur between the clinical research physician ( CRP )
/clinical research scientist 
(CRS )and the invest igator to determine if the patient may  cont inue in the study .  The 
investigator must obtain documented approval from the Lilly CRP /CRS to allow the 
inadvertent ly enro lled pat ient to conti nue in the study  with or wi thout treatm ent wi th study  drug .
In addi tion, pati ents will  be discont inued fro m the study  drug and from  the study  in the fo llowing 
circumstances:
Enrollment in a ny other clinical trial involving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .

I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 25
LY3164530Invest igator/Physician Decisio n
othe invest igator/physician decides tha t the pati ent shoul d be discontinued from the 
study or study drug
PatientDecision
othe patientrequests to be discont inued from the study or study drug
Sponsor Decisio n
oLilly stops the study  or stops the patient’s participation in the study  for medical, 
safety, regul atory , or other reasons consistent with applicable laws, regulat ions, 
and GCP
The patient has radiographic progressive disease or significant symptom atic disease 
deteri oration characterized as progression of disease ,in the opi[INVESTIGATOR_3078] n of invest igator ,in the 
absence of radiographic evidence of progressive disease .
The patient experiences unacceptable toxicit y.
The patient is nonco mpliant with study  procedures and/or treatment (Section 7.6).
A dose cannot be administered within 28 days of the prior dose due to an AE(except as 
noted i n Section7.2.5.1 ).
6.3.2. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ethical review board 
(ERB) of the study  site judges it necessary for any  scientific, m edical , safet y, regul atory , ethi cal, 
or other reason s consistent with applicable laws, regulat ions, and GCP .
6.3.3. Discontinuation of the Study
The study  will be di scontinued if Lilly , 
while considering the rights, safet y, and well -being o f the 
patient(s), judges it necessary  for any  scientific, medi cal, safet y, regulatory , ethi cal, or other 
reasons consistent with applicable laws, regulations, and GCP .
I7H-MC-JNBA (b) Phase [ADDRESS_418031] igative 
sites by [CONTACT_11007] .  Detailed instructions for the reconstitut ion of the study  drug and the preparation 
of the different dilut ions will be provided sepa rately  by [CONTACT_1034] .
LY3164530 should be stored refrigerated at 2 to 8°C .
7.2. Study Drug Administration
The invest igator or designee is responsible for:
explaining the correct use of the investigational agent and planned duration of each 
individual’s treatm ent to the si te personnel or pati ent
verifying that instructions are fo llowed properly 
maintaining accurate records of study  drug di spensati on, destructi on,and co llection
returning or destroying all unused m edicat ion to Lilly or its designee at the end of the 
study .
Patients will  be instructed to contact [CONTACT_240220] a com plaint 
or probl em with the study  drug (s)so that the situatio n can be assessed.
7.2.1. Dosing Schedule
Fordoses ≤[ADDRESS_418032] sites to extend the infusio n time for up to 3hours for 
doses >1000 mg . 
LY3164530 will be administered on Day s 1 and 15 every  28 days (Schedule 1) or on Days 1, 8, 
15, and 22 every  28 days (Schedule 2).  The assigned dose, schedule, and duration o f infusio n of 
LY3164530 will be provided by [CONTACT_17190] a patient registrati onform.A patient will be 
assigned to either Schedule 1 or Schedule 2 and will be maintained on that schedule for the 
durati on of  therapy .  Subsequent doses and/or infusion t imes should be adjusted as described in 
Secti on 7.2.5 .
7.2.2. Dose Escalation 
[IP_ADDRESS]. Dose -Limiting Toxicity Determination  
Dose -limit ing toxicit y is defined as an AEduring Cycle 1that is consi dered by  [CONTACT_338269]3164530 and fulfills any one of the fo llowing cri terion using 
the Nati onal Cancer I nstitute(NCI) Commo n Termino logy Criteria f or Adverse Events 
(CTCAE) v 4.03:
  Grade 3 non -hematol ogical toxicity.  Excepti ons will be made for:
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 27
LY3164530nausea, vo miting,diarrhea, and consti pation that can be controlled with 
treatm ent.  Grade [ADDRESS_418033] ing m ore than 48 hours despi[INVESTIGATOR_338247].
Grade 3 rash that resolves with treatm entto ≤Grade 1 within 14 days
Grade [ADDRESS_418034] treatment
Grade 3 elevations of ALT and/or AST lasting fewer than [ADDRESS_418035] igator and Lilly CRP/CRS .
Grade 4 neutropenia or leukopenia, of>7 days duration .
Grade 4 thrombocy topeni a of any  durati on.
Grade 3 thrombocy topeni a with bleeding .
Any febrile neutropenia .
Any other significant toxicit y deemed by  [CONTACT_338270] (eg, any toxicit y that is possibly  
related to the study  drug that requi res the wi thdrawal  of the pati ent from the study  
during Cycle 1).
[IP_ADDRESS]. DLT-Equivalent Toxicities
A DLT -equivalent toxicit y is defined as an AE occurring in Cycle [ADDRESS_418036] 
met the criteria for a DLT if it had occurred during Cy cle 1 .  For individual pat ients experi encing 
a DLT -equivalent toxicit y, dose adj ustments will be m ade as outlined in Section 7.2.5 .  
At each interim analys is (as defined in Section 10.10), the rate of DLT -equivalent toxicit ies will 
be assessed.  If the rate of DLT -equivalent toxicit ies is unacceptable (eg, a DLT -equivalent 
toxicity is observed in >33% patients at a given dose level), then a safet y analysis will be 
triggered and the data will be reviewed by  [CONTACT_338271]/CRS.  If the 
findings indicate that a dose level does not h ave an acceptable safet y profile for chronic (Cycle 2 
or later) administrati on, then a l ower dose level will be chosen for further invest igation.  Thi s 
decisio n will be documented in writ ing.
[IP_ADDRESS]. Dose Escalation Method
Dose escalat ion will be driven by  a mTPI[INVESTIGATOR_12183] (Ji and Wang 2013) (Attachment 7
).  A 3+3 
design i s commo nly used in Phase 1 tri als due to i ts simple, intui tive,and pre -specified 
escalat ion rul es. However, the 3+3 method has been crit icized for being conservat ive because 
the method is dictated by  [CONTACT_338272] y arising 
from small  cohort si ze.  
Like the 3+[ADDRESS_418037], 
the mTPI m ethod is based on quant itative models that incorporate uncertaint y into the decisio n 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 28
LY3164530rules, thereby [CONTACT_338273].  In the mTPI [INVESTIGATOR_12183], the number of 
patients in each cohort is not fixed, but a minimum of 3 pati ents arerequired for this study at 
each dose (unless the rule in the table indicates to deescalate the dose due to unacceptable 
toxicity [DU]) . If 3 to 6 patients are enrolled in a cohort ,the escalat ion rule parallel sa 
traditional 3+3 design.  However, the stay/deescalati on rul e of the m TPI [CONTACT_832] m ore aggressive than 
the 3+3 design .  For instance, with 2 to 3 DLTs per6 patients enrolled, the mTPI [INVESTIGATOR_338248] ,whereas the 3+3 desi gnwoul d recommend deescalation.
Figure JNBA.1 provi des the mTPI [INVESTIGATOR_338249] 20 patients.
In Figure JNBA.1, the number of pat ients dosed at a given dose level are shown in the co lumns 
(x-axis), while the number of DLTs experienced are shown in the rows (y -axis). The rules in this 
figure will be used for each dose level evaluated ;the pat ient numbers and D LTs do not carry  
over fro m cohort to cohort .  By [CONTACT_338274], 1 of 4 pre-defined rules is used:  
E:  Escal ate the dose
S:  Stay at the same dose
D:  Deescalate the dose
D
U:  Deescalate the dose due to u nacceptable toxici ty.  The dose cannot be re-escalated
to this dose level at a future point in the escalat ion.
If agreed upon by [CONTACT_338275] (for instance ,if PK/PD data suggest that 
increasing the dose further is not ex pected to yield addit ional benefit), a more conservat ive rule 
may be applied.  For instance, if the rule indicates “E” to escalate, the dose may remain at the 
current dose level or be deescalated to a l ower l evel.
As shown in Figure JNBA.1, if 1 of 3 patients experi ences a DLT , the deci sion(located in 
column 3 row 1) is ”
S”, stay  at the same dose .  Therefore, thenext patient mustbe treated at the 
same dose level .  If 1 of 6 patients experience a DLT , the deci sion(located at col umn 6 row 1) i s 
“E”, escalate the dose.  However, if 2 of 3 patients experience a DLT the decisio n is “D”and the 
dose m ust be deescalated.
In the m TPI, t he cohort size is not fixed .  However , each cohort in this study  will contain a 
minimum o f 3patients, unl ess the escalat ion rules dictate that the dose should be deescalated due 
to unacceptable toxicity(“DU”) .  Doses can be escalated, deescalated ,and re -escalated fo llowing 
the rules in Figure JNBA .1.  Ifthe dose decisio n was “DU,”the dose cannot be re- escalated to 
that level.
Thisstudy  is designed to identify a dose level witha dose-limit ing target toxicit y rate of 30 %.  In 
realit y, the exact target toxicit y rate i s alm ost never achieved for a dose .  To thi s end, instead of
using a single target rate, the mTPI [INVESTIGATOR_338250] (EI) around the 
target toxici ty rate.  For this study, the EIis calibrated to be (28.7%, 30.1%)
,result ing in the 
rules in Figure JNBA.1.  If the observed toxicit y rate exceeds 40% and the model is st ill 
recommending “S”, the Sponsor ,in discussio n with the investigators ,may choose to deescal ate. 
Deescalat ion may not be required for toxicit ies confounded by [CONTACT_338276], particularly if 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 29
LY3164530they are deemed non -serious (eg, fat igue, anorexia), reversible , or inconsistent with the known 
toxicities of MET or EGFR inhibitors by  [CONTACT_338271]/CRS.
Figure JNBA .1. Dose -finding spreadsheet of the modified toxicity probability 
interval method showing number of patients treated at a given 
dose vs. number of DLTs observed at that dose .
The beginning dose level for Sche dule 1 was 300mg.  The starting dose level for Schedule 2 will 
be 500 m g.  The dose will be escalated by a maximum increment of 100%. If the beginning dose 
level is determined to be unacceptably  toxic, a-[ADDRESS_418038] increment will be determined by [CONTACT_941] i nvesti gators and Lilly  CRP /CRS ,and may be 
less than the maximum increment allowed in the protocol.  Safet y data will be the primary  
criteria for both the decisio n to dose -escalate and for select ing the dose to be administered in the 
next cohort.  In addit ion, if available at the time of the dose escalat ion decisio n, PK (maximum 
serum  concentrati on [Cmax], area under the serum concentration -time curve [ AUC ], and CL)
and/or PD results will be used as secondary/supporting data for dose escalat ion.  No dose 
escalat ion can occur without prior discussio n and agreement between the investigator and the
Lilly CRP or CRS; the decision will be documented in writ ing.  I ntrapatient dose escalat ions are 
not permitted.
Although an example escalat ion table is shown in
 Table JNBA. 3, alternate doses m ay be 
selected. 

I7H-MC-JNBA (b) Phase [ADDRESS_418039] pati ent is requi red to com plete a full cycle (28 day s) 
before subsequent patients can be dosed .  Subsequent patients in Cohort 1 can be dosed 
concurrent ly.Beginning wit h Cohort 2 for Schedule 1 and for all cohorts with Sch edule 2 ,
patients within a cohort can be dosed concurrently .  
The decisio n to stop dose escalat ion will be primarily driven by [CONTACT_338277].1.  Ho wever, i f PK/PD data suggest that increasing the dose further is not 
expected to yi eld addi tional benefi t, escalati on may cease.  
7.2.3. Recommended Phase [ADDRESS_418040] been enrolled .  
The RP2D will be agreed upon following discussio n between the investigators and the Lilly CRP 
or CRS and will include an assessment of safet y, PK, and PD data. AttheRP2D, the intersection 
of the numbe r of patients dosed and the number of DLTs at that dose level on the mTPI [INVESTIGATOR_338251] d indicate “S” or “E .”
7.2.4. Monitoring and Treatment Guidance for the Investigator
[IP_ADDRESS]. Infusion -Related Reactions
Due to the risk of hypersensit ivity react ions wi th any biological  agents, all  patients should 
continue to be closely mo nitored for si gns and symptom s indicat ive of an infusio n-related 
reacti onboth in the acute period (immediately  or wi thin 24 hours after dosing) and up to several 
days to a few weeks after dosing for del ayed react ions.  In Cycles [ADDRESS_418041] igator.   Moni toring shoul d be 
perform ed in an area where resuscitat ion equipment and other agents ( eg, epi[INVESTIGATOR_238], 
corticosteroi ds) are readily  available .  
Per the CTCAE v 4. [ADDRESS_418042] igators are encouraged to Dose Level
(Cohort)Schedule 1 Dose Schedule 2 Dose
-1 100 mg 400 mg
1 300 mg 500 mg
2 600 mg 600 mg
3 1000 mg 700 mg
4 1250 mg
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 31
LY3164530use the AE term “Infusio n-related React ion” and any addit ional term s (including those not listed 
here) that best describe the event .  
Secti on 7.2.[ADDRESS_418043] an infusio n-related reaction to LY 3164530
, 
all attem pts shoul d be made to obtain an an ti-LY3164530 antibody  blood sam ple 
(immunogenicit y sample) as close to the onset of the event as possible, at the resolut ion of the 
event and 28days fo llowing the event.  In addition, these same samples may be assessed for 
levels o f LY3164530 and for PD m arkers to provide informat ion on the nature of the 
infusio n-related reacti on.  Immunogenicit y samples will be co llected during the fo llow
-up visit 
for all patients.  The procedure for sample co llection and handling is described in a separate 
procedural  manual.
If infusio n-related reacti ons are observed, premedication wit h diphenhydramine hydrochlorid e
(or equivalent), dexamethasone (or equivalent) ,or other medications as medically  indicated m ay 
be considered for future patients.  The decisio n to impleme nt prem edicati on for drug 
administration in subsequent patients will be made fo llowing a di scussi on between the 
investigators and Sponsor and will be documented in writ ing.
[IP_ADDRESS]. Skin Reactions
Skin rash is a known toxi city of EGFR inhibitors , and skin effects w ere observed with 
LY3164530 in a [ADDRESS_418044] of 
care premedicat ion for EGFR inhibitors, such as dexamethasone and/or topi[INVESTIGATOR_199]/or oral 
antibiotics, may be administered for the init ial and subsequent doses.  .
Secti on [IP_ADDRESS] and Table JNBA. 4detail  the treatment recommendat ions for LY3164530 skin
reacti ons.
7.2.5. Dose Delays and Adjustments
[IP_ADDRESS]. Dose Delays and Omissions
The following rules shoul d guide dosing:
Before each cycle of LY3164530 the following param eters are requi red:
Hem atologic:  ANC 1.5x 10 9/L, pl atelets 75 x 10 9/L, and hemoglo bin 
8g/dL.
Non-hematol ogic:  AEs must resolve to CTCAE v 4.03 Grade ≤1, or baseline .  
Except ions will be made for :  alopecia,fatigue,skin reactions , 
or other 
toxicities that c anbe controlled wit h standard treatment ; these toxicit ies must 
resolve to ≤Grade 2 .
The start of a cy cle is the date of the Day  1 dose.  
For Schedule 1: If the Day  15 dose cannot be administered within 21 days of the prior 
dose (by  [CONTACT_2006]  22), i t shoul d be o mitted. The interval between LY3164530 doses must not 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 32
LY3164530be less than 14 days.  If a dose is delayed (for toxicit y or other ci rcumstances), the next 
dose should be adjusted so that there is at least a 14- day interval.

For Schedule 2:  If a dose cannot be ad ministered within [ADDRESS_418045] not be less than 7 days.  If a dose is 
delayed (for toxi city or other ci rcumstances), the next dose should be adjusted so that there is at 
least a 7-day interval. If a dose cannot be administered within 28 days of the pri or dose due to an 
AE, the patient should be removed fro m study  drug treatm ent and shoul d com plete subsequent 
follow-up (Table JNBA. 4).  
If the patient has completed the init ial on -study  radiographic assessment (eg, at the end of 
Cycle 2) and is cont inuing to receiv ebenefit fro m therapy, delays of greater than 28 day s  
may be acceptable if agreed upon by [CONTACT_338278] .  For instance, if a 
patient has a non –
drug-related AE such as prolonged flu, the pati ent m ay cont inue on therapy 
if, in the opi[INVESTIGATOR_3078] n of the invest igator, he/she is showing benefit fro m therapy  and has 
recovered sufficient ly from the AE .  
Adelay  of no m ore than 7days because of ho lidays, weekends, inclement weather, or other 
justifiable events will be permitted and will not be counted as a protocol deviat ion.  
[IP_ADDRESS]. Dose Adjustments
Dose adjust ments should fo llow the gui dance in Table JNBA. 4.
For pati ents requi ring dose reductions, r eescalat ion to the original assigned LY3164530 dose is 
not allowed.  T he patient must be maintained at a reduced dose level for all remaining cycles.
I7H-MC-JNBA (b) Phase [ADDRESS_418046] occurrence  Decrease the LY3164530 infusion rate by 50% and monitor closely for any 
worsening.  For subsequent infusions, premedicate with diphenhydramine 
hydrochloride; additional premedication may be administered at the investigator’s 
discretio n.  
Grade [ADDRESS_418047] occurrence Stop LY3164530 infusion. Administer diphenhydramine hydrochloride and
acetaminophen for fever and oxygen .  Resume infusion at 50% of previous rate 
once infusion -related reactio n has resolved or decreased to Grade 1 in severity, 
and monitor closely for any worsening .  
For subsequent infusions, premedicate with diphenhydramine hydrochloride; 
additional premedication may be administered at the investigator’s discretion .  
The reduced rate should be used for all subsequent infusions.
Grade 1 or 2
Second occurrenceAdminister dexamethasone .
For subsequent infusions, premedicate with diphenhydramine hydrochloride, 
acetaminophen, and dexamethasone .  The reduced infusion rate should be used 
for all subsequent infusions.
≥Grade [ADDRESS_418048] infusion tubing from the 
patient .  
Administer diphenhydramine hydrochloride, dexamethasone, bronchodilators for 
bronchospasm, and other medications/ treatment as medically indicated .
Patients must not receive any further LY3164530 treatment.
Skin 
reactions 
(eg, acne-
like rash)Grade [ADDRESS_418049] occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 following the rules in Section 
[IP_ADDRESS] . Treatment with topi[INVESTIGATOR_199]/or oral antibiotics should be considered .
Grade 3
Second occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 following the rules in Section 
[IP_ADDRESS] .  Dose reduce to the dose level used for the previous cohort for second 
occurrence.   Treatment with topi[INVESTIGATOR_199]/or oral antibiotics should be considered .  
Grade [ADDRESS_418050] not receive any further LY3164530 treatment .
Other 
toxicities≥Grade [ADDRESS_418051] occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 or baseline following the 
rules in Section [IP_ADDRESS] . Based on the investigator’s discretion ,the full dose of 
LY3164530 may be administered or the dose may be reduced to the next lowest 
dose level. Ifevent recurs at same grade ,then dose re duce LY3164530 to the 
next lowest dose .  
≥Grade 3
Second occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 or baseline following the 
rules in Section [IP_ADDRESS] . If event recurs at same grade ,then dose reduce 
LY3164530 to the next lowest dose.  Exceptions may be made for transient 
changes in electrolytes that respond to treatment .
Abbreviation:  CTCAE = Common Terminology Criteria for Adverse Events.
Note:  In addition, the dose may be reduced to the next lowe rlevel for any toxicity at the discretion of the 
investigator.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 34
LY31645307.3. Method of Assignment to Treatment
Patients who m eet all cri teria for enrollm ent will be assigned to receive LY3164530 in this study .  
Before each pat ient’s enro llment into the study, an eligibilit y check must be conducted between 
the invest igational site and the Lilly clinical  research personnel to confirm that each patient 
meets all enrollment criteria.  Upon confirmation of eligibilit y, the Sponsor will confirm the 
dose, schedule, infusion duration, and ident ificat ion number assignment for each patient.  
7.4. Blinding
This is an open -label study .
7.5. Concomitant Therapy
In the absence of clinical experience with LY3164530, patients shoul d be clo sely evaluated to 
ensure ident ificat ion of exacerbat ionsof known side effect sof concomi tant m edicat ions.  These 
shoul d be reported immediately to the Sponsor .  No other chemotherapy, radiotherapy, 
immunotherapy , herbal supplements intended to treat the cancer , cancer -related horm one 
therapy , or experimental drugs will be permitted while the patients are on this study .An 
exception will be made for prostate cancer patients continuing GnRH agonist therapy  or breast 
cancer patients continuing ant iestrogen therapy  (eg, an arom atase inhibitor). However, the 
treatm ent shoul d have been started at least [ADDRESS_418052] dose of stud y drug.  Patients on 
stable doses of bisphosphonates or denosumab are allowed to continue.  These agents should not 
be initiated wi thin the 4 weeks prior to study  enrollment or at any  point while on the study .  
Palliat ive radiotherapy of no more than 14 ca lendar days to a solitary  (non -skull) skeletal 
metastasis will be permi tted fo llowing discussio ns between the invest igators and the Sponsor , so 
long as the skeletal metastasis is not the primary  measurable l esion and the patient has not 
developed another r eason for study discont inuat ion.  
In addit ion, any disease progression requiring other forms of specific antitumor therapy  will 
necessitate early discont inuat ion from the study .  Appropriate documentation for all forms of 
prem edicat ions, supportive care, and conco mitant medicat ions m ust be captured on the case 
report form (CRF) .  Repl acement horm onal therapy  initiated before study  entry  will be allowed.
Patients shoul d receive full supportive care during the tri al.  R outine prophylact ic use o f 
granulocy te co lony
-stimulat ing factors (G -CSF) is not permitted during this study .  Should the 
use of hematopoiet ic co lony-stimulat ing factors (CSFs) be necessary , follow the American 
Society of Clinical  Oncol ogy (ASCO) recommendations for the use of CSFs (Smit h et al . 2015).  
Erythropoi etin and packed red bl ood cell  (RBC )transfusio n may be used according to ASCO 
guidelines (Rizzo et al. 2008) if clinically  indicated at any  time during the study .Platelet 
transfusio ns m ay be used according to ASCO guidelines (Schiff er et al . 2001).
All conco mitant m edicat ions, including premedication, shoul d be recorded throughout the 
patient’s parti cipati on in the study on the electronic case report form ( eCRF ).
I7H-MC-JNBA (b) Phase [ADDRESS_418053] igator.  As a result, a patient’s compliance with study drug administration is ensured.  
Patients shoul d attend scheduled clinic visit s and must comply  with study criteria under thei r 
control .  Deviat ion(s) fro m the prescribed dosage regimen should be recorded on the eCRF.  
7.6.1. Evaluable Patients
Patients who wi thdraw from  the study  before receiving study  drug will be replaced and will not 
be included in the safet y or efficacy assessments.  Safet y analyses will be conducted on all 
patients who have been exposed to study drug, regardless of whether they are deemed evaluable 
for the assessment of a dose level.
Any pat ient who i s discont inued fro m the study  before com pleting 1cycle of LY [ADDRESS_418054] igator(s) and the Lilly CRP or CRS to ensure adequate PK data, 
unless accrual to that cohort has stopped due to a DLT.
I7H-MC-JNBA (b) Phase [ADDRESS_418055] igator’s 
Brochure .  Thi s Phase 1 study  contains safet y monitoring that will permit init ial characterizat ion 
of the safet y profile of LY 3164530 in pat ientswith advanced or m etastatic cancer .  Study  
procedures and their timing, including co llection of patientsamples, are described in the Study  
Schedule ( Attachment 1 ).
Standard laboratory  tests will be performed as lis ted in Attachm ent [ADDRESS_418056] meet the minimium requirements outlined in  
Table JNBA. 5.
The timing of all safet y evaluat ions is shown in the Study  Schedule ( Attachm ent 1 )
.  Table 
JNBA. 5presents a summary of AE and SAE reporting guidelines.  Table JNBA. 5also shows 
which database or sy stem  is used to store AE and SAE data .
8.1.2. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed rega rdless of applicable regulatory  
requi rements that m ay be less stringent.  A clinical study  AE is any untoward medical occurrence 
in a pati ent or clinical invest igation subject administered a pharmaceut ical product and which 
does not necessarily  have a caus al relati onship wi th this treatm ent.  An AE can therefore be any  
unfavorable and unintended sign (including an abnormal laboratory  finding), symptom, or 
disease tem porally associ ated wi th the use of m edicinal (invest igational) product whether or not 
related to the medicinal (invest igational) product.   
Any clinically  significant findings from labs, 
vital sign m easurements, and so on that occur should also be reported to Lilly or its designee as 
I7H-MC-JNBA (b) Phase [ADDRESS_418057] igator, monitor, and Sponsor will review the collected data regularly for evidence of 
AEs.  All pat ients will be assesse d routinely for AEs as outlined in the study  schedule.  All AEs 
observed will be graded using CTCAE v 4.03.
The CTCAE v 4.03will serve as the reference document for choosing appropriate termino logy 
for, and grading the severit y of, all AEs and other symptoms. All AEs observed will be graded 
using CTCAE v 4. 03.  Any  minor versi on of CTCAE v 4.0 ( eg, v 4.03 ) may be used for thi s 
study .  Minor CTCAE v 4.[ADDRESS_418058] igator will 
be responsible for selecting the appropriate sy stem organ cl ass and as sessing severi ty grade 
based on the intensit y of the event.  Note that both CTCAE term (actual or coded) and severit y 
grade must be selected by  [CONTACT_338279].  Thi s collection is in 
addition to verbat im text used to describ e the AE.
In addit ion to collect ing the AE verbat im, the CTCAE term, and the CTCAE severit y grade, AE 
verbat im text will also be mapped by [CONTACT_338280] (MedDRA) dictionary.
Cases of pregnancy that occur during maternal or paternal exposures to study  drug shoul d be 
reported.  Data on fetal outcome and breastfeeding should be collected, if feasible, for regulatory 
reporting and drug safet y evaluat ion.  
Upon documen tation of  pregnancy , the patient m ust be 
removed from  the study  and treatm ent wi th study  drug m ust be stopped immediately.
For all enrolled pat ients, study  site personnel will record the occurrence and nature of each 
patient’s preexist ing condit ions, including clinically  significant si gns and symptoms of the 
disease under treatment in the study .  While the pati ent is on study , site personnel will record any  
change in these preexist ing condit ion(s) and the occurrence and nature of any  AEs.  In addit ion,
all AEs related to protocol  procedures are reported to Lilly or desi gnee.
If a patient's dosage is reduced , delayed, or omitted; or if treatm ent is discont inued as a result of 
an AE, study  site personnel  must cl early  report to Lilly or its desi gnee via desi gnated data 
transmissio n methods the ci rcumstances and data leading to any  such dosage modificat ion or 
discontinuat ion of treatm ent. 
Invest igators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure and/or study drug via eCRF/electroni c data entry .
[IP_ADDRESS]. Serious Adverse Events
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
Planned hospi [INVESTIGATOR_338252]’s medical history  at the time of study enrollment shoul d not be 
considered SAEs.  Hospi[INVESTIGATOR_338253] a precipi[INVESTIGATOR_338254] 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 38
LY3164530clinical AE ( eg, for the administration of study  therapy  or other protocol -requi red procedure) 
should not be consi dered SAEs.
An SAE is any  AEduring thi s study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hos pi[INVESTIGATOR_3094] (except for study  drug 
administration)
a life- threatening experience ( ie, immediate ri sk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
considered significant by  [CONTACT_92355].
Important m edical events that may not result in death, be life -threatening, or require 
hospi [INVESTIGATOR_338255], based on appropriate medical judgment, they  
may jeopardize the patient and may require medical or surgical interven tion to prevent one of the 
outcom es listed in this definit ion.  
Serious adverse events due to disease progression, including death, should not be reported unless 
the invest igator deems them to be possibly related to the study  drug.
Study  site personnel  must al ert Lilly or its desi gnee of  any SAE within [ADDRESS_418059] igator becomes aware of SAEs occurring after the patient’s participation in the trial 
has ended, and the invest igator believes t hat the SAE is related to a protocol procedure or study 
drug, the invest igator should report the SAEs to the Sponsor , and the SAEs will be entered in the
Lilly Safety  System .
Inform ation on SAEs expected in the study  popul ation independent of drug exposure and that 
will be assessed by  [CONTACT_338281]’s Brochure .  
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting
Data on SAEs that occur before the end of trial will be stor ed in the col lection database and the 
Lilly S afety  System .
[IP_ADDRESS].1. Prior to Administration of Study Drug
During screening, all AEs and SAEs (regardless of relatedness to protocol procedures) are 
collected after the patient has signed the ICF.  For pati ents who do not enroll in the trial ( eg, have 
not been exposed to LY3164530), only AEs and SAEs related to protocol procedures are 
requi red to be collected .  
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 39
LY31645308.[IP_ADDRESS]. On Therapy
All AEs and SAEs, regardless of relatedness to study  drug or protocol procedures, occurring 
while the pati ent is receiving study  drug m ust be reported to Lilly or its designee.  A patient is 
considered to be receiving study  drug from  the time he/she receives the first dose of study  drug 
to when he/she receives the last dose of study  drug.
[IP_ADDRESS].3. Follow -Up Vis it
All AEs and SAEs, regardless of relatedness to study  drug or protocol procedures, occurring 
during the fo llow-up visit (Visit 801) must be reported to Lilly  or its designee .  The fo llow-up 
visit starts following the last dose of study  drug.  At the end of the f ollow-up visit, the patient 
will be required to have specific safet y assessments ( Attachment 1 ).  The timing of these 
assessments is 28 days ± [ADDRESS_418060] of the patient to start a new ant i-cancer treatment prior to 
the scheduled end of the fo llow-up visit period, the fo llow-up visit duration may  be shortened .  
In thi s case, follow up assessments , including AE and SAE reporting shoul d be co mpleted prior 
to the init iation o f the new therapy .  
Following the safet y assessments thatmark the planned end of the fo llow
-up visit (Visit 801), the 
patient will be discont inued fr om the study , unless there is an ongoing AE or SAE that is 
possibly  related to study  drug.  Particular focus should be placed on patients that have abnorm al 
electroly tes, as electroly te depl etion is known to occur for >6 weeks after EGFR monoclonal 
antibody therapy .  
If a patient has anongoing AE or SAE possibly related to LY3164530 ( eg, abnormal 
electroly tes), the pati ent shoul d be f ollowed unt il the event is resolved, the event is no longer 
considered to be study  drug-related, the event becomes stable o r returns to baseline, a new 
treatm ent is init iated for the patient, or the patient dies or is lost to fo llow-up.  Any subsequent 
follow-up(s) for AEs will be no more than 28 day s ± 5 days in duration .  
After the fo llow-up visit (Visit 801), AEs are not r equired to be reported unless the invest igator 
feels the AEs were related to either study  drug, drug delivery  system , or a protocol  procedure.  If 
an invest igator becomes aware of an SAE believed to be related to protocol procedures or study  
drug, the inve stigator should report the SAE to the Sponsor (Attachment 6) , and the SAE will be 
entered in the Lilly  Safety  System .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are not listed in the
Development Core Safet y Informati on in the Investi gator’s Brochure and that the invest igator 
ident ifies as related to study drug or procedure.  The US21 CFR 312.32, the EUClinical Trial 
Directive 2001/20/EC and the associated detailed guidances or nati onal regulatory  requi rements 
in parti cipat ing countries require the reporting of S[LOCATION_003]Rs.  Lilly has procedures that will be 
followed for the recordi ng and expedited reporting of S[LOCATION_003]Rs that are consistent with global 
regul atory  regulat ionsand the associated detailed guidances.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 40
LY31645308.1.2.4. Summary of AE/SAE Reporting Guidelines
The AE and SAE reporting guidelines are summarized in Table JNBA. 5.
Table JNBA .5
. Adverse Event and Serious A dverse Event Reporting Guidelines 
for Study JNBA  
Study Period TimingTypes of AEs/SAEs 
ReportedDatabase used for 
Collection
Screening/Baseline Starts at the signing of informed 
consent and ends just before the 
first dose of study drugPreexisting conditions
All AEs and SAEs 
regardless of relatedness Clinical database 
and LSS
On therapy Starts at first dose of study drug 
and ends at last dose of study 
drugAll AEs and SAEs 
regardless of relatednessClinical database 
and LSS
Follow -up Visit
(Visit 801)Starts just after the last dose of 
study drug and ends when end of 
study safety assessments are 
completed 28days (5 days)  
after last dose of study drugAll AEs and SAEs 
regardless of relatednessClinical database 
and LSS
Subsequent Follow -ups , 
if necessary for patient 
monitoring for ongoing 
related AEs (continuation 
of Visit 801)Follow -ups no mo re than 28 day
intervals(5 days) and are 
continued until the criteria in 
Section [IP_ADDRESS].3 are metOngoing AEs possibly 
related to study drug, or 
protocol procedures.
All SAEs related to protocol 
procedures or study drugClinical database 
and LSS
Patient no longer on 
studyAll SAEs related to protocol 
procedures or study drug 
that the investigator 
becomes aware ofLSS
Abbreviations:  AE = adverse event; LSS = Lilly Safety  System; SAE = serious adverse event.
8.1.3. Other Safety Measures
[IP_ADDRESS]. Electrocardiograms
For each patient, a 12 -lead di gital ECG will  be collected according to the Study  Schedule 
(Attachm ent 1 and Attachment 4).  Patients must be supi[INVESTIGATOR_17044] [ADDRESS_418061] ion and remain supi[INVESTIGATOR_57966].  During Cycle 1, 
triplicate ECGs will be done as specified in the Study  Schedule ( Attachm ent 1 ).  Beginning with 
Cycle 2 and beyo nd, only a single ECG will be required (Attachm ent 4 ).
Electrocardiograms may be obtained at addit ional times ,when clinically indicated .  Collect ion of 
more ECGs (m ore replicates) than expected at a particular time point is allowed to ensure high 
qualit y records .  
Electrocardiograms will be interpreted by  
a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible to determine whether 
the pati entmeets entry  criteria and for immediate patient management, should any cl inically 
relevant findings be identified.  
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 41
LY3164530If a clinically significant quantitative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the patientfor symptom s (eg, palpi[INVESTIGATOR_814], near syncope, 
syncope) to dete rmine whether the patientcan continue in the study .  The invest igator or 
qualified designee is responsible for determining if any change in patientmanagement i s needed 
and must document his/her review of the ECG printed at the time of evaluation fro m at least 1 of 
the replicate ECGs from each t ime point.
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designated by  [CONTACT_11007] .  
The central ECG laboratory  will perf orm a basic quali ty control  check ( eg, dem ographics and 
study  details), and will then store the ECGs in a database.  At a future time, the stored ECG data 
may be overread at the central ECG laboratory  for further evaluat ion of machine -read 
measurements or to meet regulatory  requi rements.  
The m achine -read ECG intervals and heart rate may be used for data analysis and report writing 
purposes ,unless an overread of the ECGs is conducted prior to complet ion of the final study  
report (i n which case the overread data would be used).
8.1.4. Safety Monitoring
The Lilly CRP or CRS will monitor safety  data throughout the course of the study .  
Representatives from Lilly Glo bal Patient Safet y will specifically  monitor SAEs.  
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.  To ensure patient safety and comply wit h regulatory  guidance, the 
investigator is to consult with the Lilly CRP/CRS regarding collect ion of specific reco mmended 
clinical informat ion and fo llow-up laboratory  tests (see Attachm ent 5 ).
If a study  patient experiences elevated ALT >5X ULN and elevated total bilirubin >2X 
ULN, clinical and laboratory  monitoring shoul d be ini tiated by  [CONTACT_3170].  
Forpatients entering the study wit h ALT >3X ULN, monitoring should be triggered at 
ALT >2X baseline.
8.1.5. Complaint Handling
Lilly collects complaints on study  drugs used in clinical studies in order to ensure the safet y of 
study  participants, m onitor quali ty, and f acilitate process and product improvements .  
Com plaint s related to concomitant drugs are reported directly to the manuf acturers of those 
drugs in accordance with the package insert.
The invest igator or his/her designee is responsible for handling the fo llowing aspects of the 
complaint process in accordance with the instructions provided for this study :
recording a comple te descri ption of the complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed complaint form within [ADDRESS_418062] igation, he/she will return a copy  of the 
product complaint form with the product.
I7H-MC-JNBA (b) Phase [ADDRESS_418063] ions in this study.
Attachm ent 2 lists the specific tests that will be performed for this study.  
Attachm ent 3 lists the PK and PD sample co llections.
Attachm ent 4 lists the ECG, chemistry ,and hematol ogy collecti on schedule .
8.2.1. Samples for Study Qualification and Health Monitoring
Blood and urine samples will be collected to determine whether patients meet 
inclusio n/excl usion criteria and to monitor pati ent heal th.Invest igators must document their 
review of each laboratory  safet y report and include a determinat ion of the clinical significance of 
abnorm al labs.
Samples co llected for specified laboratory tests will be destroyed wit hin [ADDRESS_418064] results.  Tests are run and confirmed prompt ly whenever scient ifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run, or to retain the samples until the end of the study  to confirm  that the resul ts 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply wit h 
applicable laws, regulat ions, or l aboratory  certificati on standards.
8.2.2. Samples for Drug Concentratio nMeasurements 
Phar macokinetics/Pharmacodynamics 
[IP_ADDRESS]. Pharmacokinetic Samples
At the visit s and t imes specified in Attachm ent [ADDRESS_418065] ion and handling of blood sam ples will be provi ded by  [CONTACT_1034] .  The actual date 
and time ( 24-hour cl ock time ) of each sampling will be recorded.
These samples will be analyzed at a laboratory  designated by  [CONTACT_1034] .  Serum concentrations 
of LY3164530 will be assayed using a validated ELISA method.
The PK samples will be stored at a facilit y designated by  [CONTACT_1034] .
Bioanaly tical samples collected to m easure LY3164530 will be retained for a maximum of [ADDRESS_418066] pati ent visi t for the study .
[IP_ADDRESS]. Pharmacodynamic Samples
At the visit s and t imes specified in Attachm ent [ADDRESS_418067] -specific targets maybe explored to 
determine changes in potential bio markers such as circulat ing levelsofthe MET ligand HGF,  
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 43
LY3164530EGFR ligands (eg ,EGF, TGFalpha), MET/ECD, and EGFR/ECD. These samples may be used 
for exploratory  research on new bio markers related to the MET /HGF and EGFR pathway .  In 
addition, exploratory  sample sto assess proteomic panel may be collected .  A maximum of 3 
timepo ints may be remo ved per dosing schedule during the study  if warranted and ag reed upon 
between both the investigator and Lilly.
Bioanaly tical samples collected to m easure PD bi omarkers will be identified by  [CONTACT_338282] (coded) and retained for a maximum o f [ADDRESS_418068] ion, handling, and shipment of the patients’ samples will be provided by  [CONTACT_1034].  The 
samples will be analyzed at a laboratory  designated by  [CONTACT_1034].  
8.2.3. Samples for Tailoring Biomarker s
Collect ion of tum or sam ples f or tail oring bi omarker research i s a com ponent of this study .  
The fo llowing samples are r equired for biomarker research:
Pre-treatm ent tum or tissue 
Blood, plasma, and/or serum samples .
The fo llowing samples are o ptional samples and shoul d be collected from pat ients in the study  
when possible :
If a patient has available archived tumor tissue previously taken to evaluate the patient’s 
disease , a small am ount of  this ti ssue will be requested for biomarke r research
On treatment and/or p ost-treatm ent tum or tissue.
These samples are described in the fo llowing sections.
[IP_ADDRESS]. Tumor Tissue
Apretreatm ent tum or biopsy  shoul d be obtained prior to the first dose of LY3164530 . However, 
for pati ents who have disease rec urrence/metastasis in technically  challenging sites to ob tain 
biopsies or who have t issue available from a prior post -treatm ent bi opsy  and have not received 
intervening therapy , the invest igator and Sponsor may agree to omit the pretreatment biopsy.  
The d ecisio n must be docum ented in writ ing prior to the patient receiving the first dose of study  
drug and will not constitute a protocol vio lation.  Tissue will be taken by [CONTACT_338283] .  Due diligence should be used to ensure that t umor specimen (not normal 
adjacent or tum or margins) is provi ded.  Pathology notes accompanying the tissue may also be 
requested.
In addit ion to the new biopsy  tissue, pri or archived tissue will be requested.  Pretreatment 
archived formalin -fixed paraffin -embedded tumor tissue should be in a who le block, partial 
block, or unstained slides. Bone samples should not be submitted .  Any blocks or slides 
submitted for analysis will eit her be returned to the site upon request or discarded wi thin [ADDRESS_418069] patient visit for the trial .  
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 44
LY3164530Following treatm ent wi th LY3164530, opti onal on -treatment ( eg, while st ill on study therapy) 
and/or post -progression biopsies ( eg,following docum entati on of  progressive diseas e on Study  
JNBA) for bio marker research fro m patients willing to consent may be collected if safe and 
feasible and upon notificat ion and discussio n with the Sponsor .  In particular, post -treatment 
biopsies fro m lesions in pat ients who have received clinica l benefit and subsequent ly progress 
may help ident ify mechanisms of resistance to LY3164530.  Post -progression biopsies should be 
perform ed pri or to the start of subsequent cancer treatment.  However, the procedure should not 
impede or delay the planned ca ncer treatm ent.
In archived and pre -treatm ent ti ssue samples ,an evaluat ion of analy tes related to the m echanism 
of action of  MET -EGFR inhibit ion and cancer pathobio logy may be perform ed to assess any 
potenti al correl ation with response to LY3164530.  For example, the expressio n of MET protein , 
EGFR protein , HGF, and EGFR ligands may  be assessed by [CONTACT_9064]  (IHC)and/or 
fluorescence in situ hybridizat ion (FISH) .  In addi tion, mutation status ,allelic imbalance, and/or 
copy  number variat ions of cancer -related genes including, but not limited to ,MET , HGF , EGFR , 
KRAS , HRAS , NRAS , BRAF , may be analyzed at a laboratory  designated by  [CONTACT_1034] .  Tumor 
samples may  also be analyzed to explore potential tumor gene signature(s) associated with 
response to LY3164530 therapy .  
[IP_ADDRESS]. Blood Samples for Pharmacogenetic Evaluations
There i s growing evidence that genetic variat ion may impact a pati ent’s response to therapy .  
Variable response to therapy  may be due to genetic determinants that impact drug absorption,
distribut ion, metabo lism, and excretion, the mechanism of act ion of the drug, the disease 
etiology and/or the m olecular subt ype of the disease being treated. Therefore, where local 
regul ations and ERBs allo w, a bl ood sam ple will be collected for pharmaco genet ic analysis .  
In the event of an unexpected AE or the observat ion of unusual response, the pharmacogenetic 
biomarker samples may  be genoty ped and analysis may  be perform ed to eval uate a genet ic 
associ ation with response to LY3164530.  These investigations may be limited to a focused 
candidate gene study  or, if appropri ate, genom e-wide analysis may be performed to identify 
regions of the genome associated with the variability  observed in drug response . The 
pharmacogenet ic biomarker samples wi ll only  be used for invest igations rel ated to di sease and 
drug or class o f drugs under study  in the context of this clinical program. They  will not be used 
for broad expl oratory  unspecified disease or population genet ic analysis.
The samples will be coded with the pati ent number and stored for up to a maximum of [ADDRESS_418070] pati ent vi sit for the study  at a f acility selected by  [CONTACT_1034] .The samples and any  
data generated from them can only be linked back to the patient by  [CONTACT_338284]. The durati on allows the Sponsor to respond to regulatory  requests rel ated to the study  
drug.
Samples will  be destroy ed according to a process consistent with local regulat ion.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 45
LY31645308.2.3.3. Exploratory Biomarker Blood Samples 
In addit ion to bl ood sam ples, p lasma samples to study  circulat ing biomarkers associated with 
response to LY3164530 therapy , the underlying cancer, or cancer- related condi tionswill be 
collected.  This analysis may include, but is not limited to, circulat ing microribonucleic acids 
(micro RNAs )and cell -free tum or DNA .  These analyses may  empl oy targeted or hi gh-
throughput sequencing approaches. For this purpose, the results of these analyses will be 
correl ated wi th clinical  efficacy data .  The samples will be coded with the patient number and 
stored for up to a maximum of 15years.
8.2.4. Samples for Immunogenicity Research 
Blood sam ples f or immunogenicit y testing will  be collected to determine ant ibody  producti on 
against LY3164530 .  Immunogenicit y will be assessed by  a validated assay  designed to detect 
anti-drug ant ibodies (ADAs) in the presence of LY3164530 antibodies may be further 
characterized and/or evaluated for their abilit y to neutralize the activit y of LY3164530 .  The 
presence of ADAs and neutralizing ADAs may be compared to any  changes in expected PK/PD 
param eters.  In the event of any  AE suspected of being related to immunogenicity, the presence 
of ADA smay also be evaluated.   A portion of the sample taken for immunogenic ity testing may  
be used for PK analysis, in the setting of infusio n-related reacti ons.
Samples may  be stored for up to a maximum  of [ADDRESS_418071] ive of the study  is to docum ent any ant itumor activit y.  Ref er to Attachment 1
for details regarding the timing of specific efficacy measures.  
Each patient will be assessed by  [CONTACT_45332] m ore of the fo llowing radi ologic tests for tum or 
measurement:
Com puted tom ography  (CT) scan
Magnet ic resonance imaging (MRI)
Each patient’s full extent of disease will also be assessed with :  
Tumor measurement by  [CONTACT_393] 1.1 (Ei senhauer et al. 2009)
Evaluat ion of tumor markers, if indicated
Evaluat ion of the ECOG performance status .
In rare circumstances, historical radio logic exams for RECIST criteria that are obtained greater 
than [ADDRESS_418072] be di scussed wit h the 
Sponsor and documented in writ ing.
I7H-MC-JNBA (b) Phase [ADDRESS_418073] ive response, using t he sample method that was used 
at baseline.  Ifa pati ent is discont inued fro m the study , repeat radi ology assessments m ay be 
omitted if clear clinical signs of progressive disease are present.
8.4. Procedure/Sampling Compliance
Every  attem pt will be m ade to en roll patients who have the abilit y to understand and co mply 
with instructi ons.  Noncom pliant pati ents m ay be discontinued from the study .
The collection t imes of safet y assessments, PK samples, PD samples, and efficacy measurements 
are given as targets, to be achieved wit hin reasonable limits.  The scheduled time po ints may be 
subject to minor alterations; however, the actual collect ion time must be correctly recorded on 
the eCRF andlab requisit ion form. 
The scheduled co llection times may be modified by [CONTACT_338285] y 
and PK informat ion obtained during the study .  Any  major m odificat ions that might affect the 
conduct of the study , pati ent safet y, and/or data integrit y will be detailed in a protocol 
amendment.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 47
LY31645309.Data Management Methods
9.1. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
Sponsor start-up training to instruct the investigators and study  coordinators.  This 
session will give instruction on the protocol, the complet ion of the eCRFs, and study  
procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion
conduct a qualit yreview of the database .  
In addit ion, Lilly or its representatives willperiodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_82412]/or regulatory  agencies at any  time. Invest igators will be given notice before 
an audit occurs.
To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable 
data, the invest igator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source docu ments for the study .  If requested, the 
investigator will provide the Sponsor , applicable regulatory  agencies, and applicable ERB (s)
with direct access to the original source documents.
9.2. Data Capture S ystems
9.2.1. Case Report Form
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_338286] -provided electronic data capture sy stem .
For data handled by a data management third -party organization (T PO), eCRF data and some or 
all data that are related will be managed and stored electronically in the TPO system.  
Subsequent to the final database lock, validated data will be transferred to the Lilly  data 
warehouse, using standard Lilly  file transfer pro cesses.
For data handled by [CONTACT_338287], eCRF data and som e or all  data that are rel ated will 
be managed by  [CONTACT_338288]’s system .
9.2.2. Ancillary Data
Data m anaged by  a central  vendor will  be stored electronica lly in the central  laboratory’s 
database system.  Data will subsequent ly be transferred from the central vendor to the Lilly 
generic labs system and the TPO’s system .
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 48
LY3164530Bioanaly tical data will  be stored electronically in the bioanaly tical laboratory ’s databa se.  Data 
will subsequently be transferred fro m the bioanaly tical laboratory  to the Lilly  generi c labs 
system  and the TPO’s system or directly to Lilly .  
Electrocardiogram data will be stored electronically in the central database system o f Lilly’s 
centra l review organi zation.  Data may subsequently  be transferred from  the central  review 
organi zation system to the TPO’s system.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I7H-MC-JNBA (b) Phase [ADDRESS_418074] igator with the Lilly
CRP /CRS , pharmacokinet icist, and statistician .  The CRP /CRS and statistician will also be 
responsible for the appropriate conduct of an internal review for both the final study  report and 
any study -related m aterial to be authori zed by  [CONTACT_338289].
The analyses for this study  will be descript ive, except for possible exploratory  analyses as 
deem ed appropri ate.  Data analyses will be provided by  [CONTACT_2715] l evels and for all patients combined 
wherever appropriate.  For continuous variables, summary statist ics will include number of 
patients (N), m ean, m edian, standard deviat ion, standard error (SE), minimum, and maximum.  
Categorical endpo ints will be summarized using N, frequency , percentages, and associ ated SE.  
Missing data will not be imputed.  Exploratory  analyses of the data that are not described in the 
protocol  will be conducted as deemed appropriate.
This is a Phase 1 study  with an open -label, dose escal ation design.  Patients will be enrolled into 
cohorts sequentially wit hout randomizat ion to dose level .  During dose e scalation , the total  
sample size per cohort will be guided by [CONTACT_203326] [INVESTIGATOR_338256] (up to 20patients per cohort before establishing the RP2D and schedule ). The total 
sample size is ant icipated to be approximately  50 pati ents.  
10.2. Patient Disposition
All patient discont inuat ions will be documented, and the extent of each pat ient’s participat ion in 
the study  will be reported.  If known, a reason for their discont inuation will be given .  
Discontinuati ons due to AE or death will be listed and summarized withcause of death further 
partitioned into AE, study  disease, or other cause and summarized.
10.3. Patient Characteristics
Patient characterist ics will include a summary of the fo llowing:
Patient dem ographics including age, sex, and screening height and weight
Baseline disease characterist ics
Prior disease -related therapi [INVESTIGATOR_014] 
Concomitant medicat ions.
Other patient characterist ics will be summarized as deemed appropriate.
10.4. Safety Analyses
All patients who have been exposed to LY3164530 will be evaluated for safet y and toxi city.  
Adverse event terms and severit y grades will be assigned by [CONTACT_338290] v 
4.03.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 50
LY3164530Safety analyses will include summaries of the fo llowing:
AEs, including severit y and possible rel ationship to study  drug
dose adjust ments (reductions, omissio ns,and del ays)
laboratory  values 
vital signs 
DLTs at each dose level
ECG s
Extent of concomitant medicat ions.
10.5. Pharmacokinetic Analyses
Pharmacokinet ic analyses will be conducted on patients who have been exposed to study drug 
and have had samples co llected.  
Pharmacokinet ic parameter estimates for LY [ADDRESS_418075], AUC 0 -τ, and AUC 0-∞of 
LY3164530.  Other noncompartmental parameters, such as t 1/2, CL, volume of distribution (V) ,
and accumulat ion rati osmay be reported.   Addit ional exploratory  analyses will be performed if 
warranted by  [CONTACT_26739],and other validated PK software programs may be used if appropriate and 
approved by  [CONTACT_338291]/PDmanagement.  The versio n of any  software used for the analysis 
will be documented and the program will meet the Lilly requirements of software validat ion.
Pharmacokinet icparameter estimates will be e valuated to delineate effects of dose 
proporti onali tyand temporal  linearit y.  Log -transform ed C maxand AUC est imates will be 
assessed to estimate ratios of geometric means and the corresponding 90% confidence intervals 
(CIs).
10.6. Pharmacodynamic Analyses
Provi ded that the data allows, PD and immunogenicit y data from  all patients maybe analyzed 
using linear and/or nonlinear fixed and mixed effects models as appropriate.  Pharmacodynamic 
and immunogenicit y data will be summarized by [CONTACT_2715], drug concentration s, and t ime from dose
for each schedule of administration .  
Potential  PD markers and immunogenicit y versus time data 
will be presented graphically for each pati ent and summarized by[CONTACT_338292] o f 
admin istrati on.  Abso lute and/or percent change from baseline for the PD markers may also be 
evaluated. Data may be log -transformed prior to summarizing if necessary.  The interpatient and 
intrapat ient variability of the PDmarkers and immunogenicit y responses may also be assessed 
where appropriate.  Baseli ne m easurements m ay be evaluated as potenti al covari ates to assess 
their relationship to relevant PD responses.
10.7. Pharmacokinetic/Pharmacodynamic Analyses
In addit ion to a standard noncompartmental assessment, and provided that the data allows, the 
LY3164530 serum concentrati on-time data may  be evaluated by  [CONTACT_338293]-based approaches as 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 51
LY3164530warranted.  Addit ional analyses ,such as exposure -response modeling using the efficacy 
endpo ints,may also be explored.
Addit ional exploratory  analyses maybe performed if warranted by  [CONTACT_26739].
10.8. Efficacy
The study  was not designed to make an efficacy  assessment.  However, any  tumor response data 
and durati on of  treatm entwill be tabul ated.
10.9. Biomarker Analyses
Biomarker assessments in this study  will focus on ident ifying markers and/or marker signatures 
that may  indicate the patients most likely  to respond or be resi stant to LY3164530 .  
In archived and pre -treatm ent ti ssue samples, bio marker data related to the MET and EGFR 
pathways and cancer pathobio logy maybe analyzed to assess any potential correlat ion with 
response to LY3164530.  These analyses may  include, but are not limited to ,MET and EGFR
protein expressio n, circulat ing DNA, s omatic mutation status ,and/or copy  number variat ions of 
MET and EGFR pathw ay-related genes (eg ,KRAS, BRAF) or genes related to cancer 
pathobi ology.  In addition, tumor sam ple based gene signature(s) may be defined and evaluated 
to explore whether they  are associated with response to LY3164530 .  In all analyses, adjust ments 
may be made to account for other baseline pat ient characterist ics, safet y, and PK/PD data .  
Unless otherwise stated, given the small sample sizes invo lved, statist ical analyses results will be 
considered exploratory  and will not consider mult iple com parison ad justments.  
10.10. Interim Analyses
Since this is a dose -escalat ionstudy , data will be reviewed on an ongoing basis during the study  
until the RP2D isdetermined.  The purpose of these ongoing reviews i s to evaluate the safet y 
data at each dose level.  A review of the data will be completed approximately after6 patients 
have been treated for at least [ADDRESS_418076] been dosed at a given dose 
level for 1 cycle o f treatm entto eval uate the safet y and tolerabilit y of LY3164530.  The interim 
analysis may include, but are not limited to, an assessment of available safet y, PK, and PD data.
Enrollment may cont inue during the interim analysis and the dose esc alation rules as outlined in 
Figure JNBA.1 will cont inue to be fo llowed.
Additionalinterim analyses may be tri ggered and may include, but are not limited to, assessment 
of available safety , PK, and PD data.
. 
I7H-MC-JNBA (b) Phase [ADDRESS_418077] 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the pati ent’s willingness to continue his or her participat ion in the study  ina timely manner.
The ICFwill be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in simple terms before the patient is entered into the study  and to document that the 
patient is sat isfied with his or her understandin g of the potenti al risks and benefi ts of 
participat ing in the study and desires to participate in the study.
The invest igator is ult imately responsible for ensuring that informed consent is given by [CONTACT_338294].  This includes obtaining the appropriate signatures and dates 
on the ICFprior to the performance of any protocol procedures and prior to the administration of 
study  drug .  
In thi s protocol , the term  "informed consent" includes all consent given by [CONTACT_338295] r legal 
representatives .  
11.2. Ethical Review
Lilly or its representatives must approve all ICFs before they  are used at invest igative sites(s).  
All ICFs must be co mpliant with the ICH guideline on GCP.  
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly before the 
study  may begin at the investigative site(s).  The ERB(s) will review the protocol as required.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current Invest igator’s Brochure and updates during the course of the study
ICF
relevant curri cula v itae.
11.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
1) consensus ethics principles derived fro m internati onal ethics gui delines, including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Scien ces 
(CIOMS) International Ethical Guidelines 
2) the ICH GCP Guideline [E6]
3) applicable laws and regulat ions.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 53
LY3164530The investigator or designee will prompt ly submi t the protocol  to applicable ERB(s).
An identificat ion code assigned by [CONTACT_338296]’s name [CONTACT_65146]’s ident ity when reporting AEs and/or other study -related 
data.
11.3.1. Investigator Information
Site-specific contact [CONTACT_246689] a separate document.
11.3.2. Protocol Signatures
The Sponsor ’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
11.3.3. Final Report Signature
[CONTACT_58003] , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The invest igator with the most enrolled pat ients will serve as the final report coordinat ing 
investigator.  If this investigator is unable to f ulfill thi s functi on, another invest igator will be 
chosen by [CONTACT_57998].
The Sponsor ’s responsible medical officer and statist ician will approve the final clinical study  
report for this study , confi rming th at, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 54
LY316453012.References
Bonine- Summers AR, Aakre ME, Brown KA, Arteaga CL, Pi[INVESTIGATOR_294777], Moses HL, Cheng N.  
Epi[INVESTIGATOR_338257] a signific ant rol e in hepathocy te growth factor 
mediated bio logical  responses in m ammary epi [INVESTIGATOR_1663]. Cancer Biol Ther . 2007;6(4):[ADDRESS_418078] to overcome resistance to EGFR -targeted therapi[INVESTIGATOR_338258]. 
Nat Med . 2013;19(11):[ADDRESS_418079] R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (v ersion 1.1). 
Eur J Cancer . 2009;45(2) :228-
247.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, 
Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, 
Johnson BE, Cant ley LC, Janne PA. MET am plificati on leads to gefitinib resistance in lung 
cancer by  [CONTACT_147873]3 si gnaling. Science . 2007;316(5827):1039 -
1043.
Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale 
and progress [published correction appears in Nat Rev Cancer . 2012;12(9):637] . Nat Rev 
Cancer . 2012;12(2):[ADDRESS_418080]-in-human dose escalat ion study  of LY2875358 (LY), a bivalent MET antibody , as 
monotherap y and in combinat ion with erlotinib (E) in pat ients with advanced cancer. J Clin 
Oncol . 2013;31([ADDRESS_418081]). Abstract 8093.
Graveel CR, Tolbert D, Vande Woude GF. MET: a crit ical player in tum origenesis and 
therapeuti c target. Cold Spring Harb Perspect Biol . 2013;5(7) :pii a009209.
Ji Y, Li u P, Li  Y, Bekel e BN . A modified toxi city probabilit y interval  method for dose -finding 
trials. Clin Trials . 2010;7(6):653 -
663.
Ji Y, Wang SJ. Modified toxicit y probabilit y interval  design: a safer and more reliable method 
than the 3 + 3 design for practical phase I trials. J Clin Oncol . 2013;31(14):1785 -17
91. 
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou -Reslan H, Carano RA, Kasm an I, Mai  E, 
Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one -
armed 5D5 ant i-
c-Met antibody , inhibi ts orthotopic pancreat ic tumor growth and improves 
survival. Cancer Res . 2008;68(11):4360-4368.
Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, 
Lamszus K. A novel one -armed ant i-c-Met antibody inhibits glio blastoma growth in vivo. Clin
Cancer Res . 2006;12(20 Pt 1):6144 -6152.
McDermott U, Pusapati RV, Christensen JG , Gray NS, Settleman J. Acqui red resistance of non -
small cell lung cancer cells to MET kinase inhibit ion is mediated by a switch to epi[INVESTIGATOR_338259]. Cancer Res . 2010;70(4):1625
-1634. 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 55
LY3164530Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, 
Yasumoto K, Matsumoto K, Yano S . Abilit y of the Met ki nase inhibitor crizotinib and new 
generat ion EGFR inhibitors to overcome resistance to EGFR inhibitors . PLOS One .
2013;8(12): e84700.
RemonJ, Mor an T, Majem M, Reguart N, Dalmau E, M arquez -Medina D, Lianes P. Acquired 
resistance to epi[INVESTIGATOR_338260]
-mutant non -
small cell lung cancer: a new era begins. Cancer Treat Rev . 2014;40(1):93 -101.
Rizzo JD, Somerfi eld MR, Hagerty  KL, Sei denfeld J, Bohlius J, Bennett CL, Cella DF, 
Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Licht in AE ;American 
Society of Clinical  Oncol ogy; American Society  of Hematol ogy. Use of epoetin and 
darbepoetin in pat ients with cancer: 2007 American Society  of Clinical Onco logy/American 
Society of Hematol ogy clinical pract ice guideline update [published correction appears in J 
Clin Oncol . 2008 Mar 1;26(7):1192]. J Clin Oncol . 2008;26(1):132 -149.
Scheving LA, Stevenson MC, Tayl ormoore JM, Traxler P, Russell WE. Integral role of the EGF 
receptor in HGF -mediated hepatocy te proliferat ion.Biochem Biophys Res Comm . 2002; 
290(1):197 -203.
Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elt ing LS, Goldsmith M, Goldstein M, 
Hum e H, M cCull ough JJ, McInt yre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, 
Troner MB, Wagnon AH ;American Societ y of Clinical Oncol ogy. Platelet transfusion for 
patients wi th cancer: clinical pract ice guidelines of the American Societ y of Clinical  
Onco logy. J Clin Oncol . 2001;19(5):[ADDRESS_418082] J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo  G, Wade JL, Wozniak AJ, Armitage JO. 
2015 update of recommendations for the use of white blood cel l growth factors: an evidence -
based clinical pract ice guideline. J Clin Oncol . 2015. doi: 10.1200/JCO.2015.62.[ADDRESS_418083], Ervin TJ , Ramlau RA , Daniel DB , Goldschmidt JH Jr , Blu menschein GR Jr , 
Krzakowski MJ , Robinet G , Godbert B , Barlesi F , Govindan R , Patel  T, Orl ov SV , Wertheim 
MS, Yu W , Zha J , Yauch RL , Patel  PH, Phan SC , Peterson AC . Randomized phase II trial o f 
Onartuzum ab in co mbinat ion with erlotinib in pat ients with advanced non -small -cell lung 
cancer. J Clin Oncol . 2013;31(32):4105-4114. 
Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body  size-based dosing 
of monocl onal ant ibodies in adult clinical trials. J Clin Pharmacol . 2009;49(9):1012-1024.
Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanak a H, 
Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, 
Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M. Hepatocy te growth factor 
expressio n in EGFR mutant lung cancer with intrinsic and acquired resistance to tyr osine 
kinase inhibitors in a Japanese cohort. J Thorac Oncol . 2011;6(12):2011-2017.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 56
LY3164530Protocol JNBA  Study  Schedule Attachment 1.
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 57Baseline Schedule
Study Period Baseline
Cycle BL
Visit0
Duration Up to 28 days
Relative Day to C1D1 ≤28 ≤14
Procedure 
CategoryProcedureComments
Study 
Entry/ 
EnrollmentInformed consent form signed (prior to conducting any 
protocol -specific tests/procedures) X
Inclusion/Exclusion evaluationX
Medical 
HistoryInitial history/preexisting conditionsX
Historical illnessesXInclude HPV status if known in tumor as part of historical assessment and denote 
on eCRF .
Physical 
ExaminationPhysical examination (including height and weight)X
ECOG performance statusX
Vital signsXIncludes blood pressure, pulse ,and temperature.
Tumor 
AssessmentRadiologic imaging according to RECIST 1.1XRadiologic assessments obtained previously as part of routine clinical care may be 
used as the baseline assessment .  This may be CT scan or MRI .
Tumor measurement (palpable or visible)X
Adverse Events Collection/CTCAE GradingX
Concomitant Medication NotationX
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 58Baseline Schedule
Study Period Baseline
Cycle BL
Visit0
Duration Up to 28 days
Relative Day to C1D1 ≤28 ≤14 ≤7
Procedure 
CategoryProcedureComments
Lab/
Diagnostic 
TestsLocal hematologyX
Local chemistryX
Local coagulationX
Local urinalysisX
Local pregnancy testXMust be done [ADDRESS_418084] dose of study drug if patient is a woman of 
child -bearing potential.  May be urine or serum specimen.
Central  ECGXTriplicate ECG.  
Biopsy of pretreatment tumor tissueXUnless the Sponsor and investigator document that the biopsy may be omitted ; 
sample should be taken only after study eligibility is confirmed  
Archived tumor tissue (only if available)XOnly for those patients that meet inclusion/exclusion criteria
Tumor markers XOnly if appropriate for the tumor type of the patient.  
Exploratory biomarker blood sample XIf possible, this sample should be collected on the same day as the biopsy.
Immunogenicity sampleX
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 59During Treatment Study Schedule 
Study Period Study Treatment Period
Cycle/Visit 1 2 3-Xa
Duration 28 days 28 days 28 days
Relative Day 
within Dosing 
Cycle1 2 3 8 15 22 1 8 15 22 1 8 15 22
Procedure 
CategoryProcedure Comments
Physical 
ExaminationPhysical exam (including 
weight and skin inspections )X X X May be completed up to 7 days prior to the treatment 
infusion. 
Vital signs X X X X X X X X X X* X X* Includes blood pressure, pulse ,and temperature . For 
Cycles 1 -2, at a minimum, vital signs should be 
obtained prior to infusion, during infusion, and at 1 
hour EOI (Section [IP_ADDRESS] ). In Cycle 3 -X, vitial signs 
should be taken predose and when clinically indicated.  
* Only need to be collected for patients on Schedule 2
ECOG performance status X X X May be completed up to 7 days prior to the treatment 
infusion
Lab/
Diagnostic 
TestsLocal hematology X X X X X X X X X X X X .  May be drawn up to [ADDRESS_418085] -dose samples should be 
drawn.  See Attachment 4
Schedule 2: In Cycle [ADDRESS_418086] -dose samples should be 
drawn.  See Attachment 4 .
Schedule 2: In Cycle [ADDRESS_418087] an infusion -related reaction to 
LY3164530, all attempts should be made to obtain 
immunogenicity sample as close to the onset of the 
event as possible, at the resolution of the event and 28 
days following the event .  A portion of the sample 
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 60taken for immunogenicity testing ma y be used for PK 
analysis .
MET and EGFR ECD
pharmacodynamic samplesX X X X X X See Attachment 3 .  
MET and EGFR ligands 
pharmacodynamic samplesX X X X X X See Attachment 3 .
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 61During Treatment Study Schedule 
Study Period Study Treatment Period
Cycle/Visit 1 2 3-X
Duration 28 days 28 days 28 days
Relative Day 
within Dosing 
Cycle1 2 3 8 15 22 1 8 15 22 1 8 15 22
Procedure 
CategoryProcedure Comments
Lab/
Diagnostic 
Tests 
(cnt’d)Proteomic blood sample X X X X X X See Attachment [ADDRESS_418088] once.  Sample can be collected at any time if 
not collected on C1D1.
Exploratory biomarker blood 
sample X X Sample to be collected C7D1.
Central ECG X X X X X X X X X X X X* X X* In Cycle 1, triplicate ECGs collected predose, at EOI, 
2 hours EOI, and 6 hours EOI on the day of dosing .  
If possible, obtain prior to any associated blood 
draws.  In Cycles 2-X, single ECGs should be 
obtained predose on the day of dosing . On non -dosing 
days,the ECG may be obtained at anytime, but if 
possible they should be obtained near to the same 
time o f day as the C1D1 ECG . See Attachment 4 .
*Schedule 2 only
Tumor markers X X If applicable to tumor type of the patient; may be 
drawn up to 3 days prior to the planned assessment.
Optional tumor biopsy X
Tumor 
AssessmentTumor measurement
(palpable or visible)X X Perform at least every [ADDRESS_418089] every other cycle (approximately every 8 
weeks) .  May be omitted if patient has clear signs of 
progressive disease .
Adverse Events Collection/CTCAE Grading X X X
Concomitant Medication Notation X X X
LY3164530 –Schedule 1 X X X X X X
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 62LY3164530 –Schedule [ADDRESS_418090] been on treatment for more 
than 1 year and are continuing to derive benefit from treatment.  This decision will be documented in writing.
LY3164530
I7H-MC-JNBA (b) Phase [ADDRESS_418091] dose of 
study therapy or, if study therapy has been omitted for an extended period, the 
date it is decided that the patient will not restart study therapy .
Duration28 5 days
Relative Day 28
Procedure 
CategoryProcedure Comments
Physical 
Examination Weight X
Vital signs X Includes blood pressure, pulse ,and temperature.
ECOG performance status X
Tumor 
AssessmentTumor measurement (palpable or visible) XPerformed if lesion is assessed as target or non -target .  Not required if 
progressive disease is documented while on treatment.
Radiologic imaging according to RECIST XThesame method of imaging used at baseline should be used for each 
subsequent assessment.  Not required if progressive disease is documented while 
on treatment or if there are clear signs of clinical progression .  
Adverse Events Collection/CTCAE Grading XAfter Visit 801, only study protocol -or drug -related events are reported .  If a 
patient has an ongoing AE or SAE possibly related to LY3164530 ( eg, abnormal 
electrolytes), the patient should be followed until the event is resolved, the event 
is no longer considered to be drug -related, the event becomes stable or returns to 
baseline, a new treatment is initiated for the patient, or the patient dies or is lost 
to follow -up.  Any subsequent follow -up(s) for AEs will be no more than 28 
days ±[ADDRESS_418092] abnormal electrolytes, as 
electrolyte depletion is known to occur for > 6 weeks after EGFR monoclonal 
antibody therapy.  
Central ECG X S ingle ECG .  
Tumor markers X If applicable to tumor type of the patient .
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 64Lab/
Diagnostic 
TestsOptional tumor biopsy X From patients willing to consent .  
Exploratory biomarker blood sample X
PK sample X
Immunogenicity sample XIn addition to the scheduled sample, if a patient should have an infusion reaction 
to LY3164530, all attempts should be made to obtain immunogenicity sample as 
close to the onset of the event as possible, at the resolution of the event, and 30 
days following the event.
If a patient requires subsequent follow -ups (eg, for an ongoing AE), an 
immunogenicity sample should be obtained, if possible.  A portion of the sample 
taken for immunogenicity testing may be used for PK analysis .
MET and EGFR ECD pharmacodynamic 
samplesX
MET and EGFR ligand pharmacodynamic 
samplesX
Proteomic blood sample X Only if patient discontinues prior to Cycle 6.
Abbreviations:  AE = adverse event; BL = baseline; C = cycle; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; D = 
day; ECD = extracellular domain; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; EGFR = 
epi[INVESTIGATOR_3506]; EOI = end of infusion; HPV = human papi[INVESTIGATOR_28597]; MET = mesenchymal -epi[INVESTIGATOR_43920]; MRI = magnetic 
resonance imaging; PK=pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 65
LY3164530Protocol JNBA  Clinical Laboratory  Tests Attachment 2.
Clinical Laboratory Tests
HematologyaClinical Chemistrya
Basophils Serum Concentrations of:
Eosinophils Alanine aminotransferase
Erythrocy te count (RBC) Albumin
Hematocrit Alkaline phosphatase
Hemoglobin Aspartate aminotransferase
Leukocytes (WBC) Blood urea nitrogen 
Lymphocy tes Calcium and io nized calcium
Monocytes Chloride
Neutrophils (segmented and bands) Cholinesterase
Platelets Creatinine
Reticulocytes Gamma -glutamyl transpeptidase
Glucose, random
Coagulation:aLDH
aPTT Magnesium
PT/INR Potassium
Sodium
Urinalysisa Total bilirubin ;if total bilirubin is increased a direct 
bilirubin should be obtained .  
Blood Total protein
Glucose Uric acid
Ketones
pH Tumo r markers (if applicable)
Protein
Specific gravity Serum or Urine Pregnancy Test (females only)a
Urine leukocyte esterase
Abbreviations:  aPTT = activated partial thromboplastin time; INR = International Normalised Ratio; LDH = lactate 
dehy drogenase; PT = prothrombin time; RBC = red blood cells; WBC = w hite blood cells .
aLocal or investigator -designated laboratory
I7H-MC-JNBA (b) Phase [ADDRESS_418093] end of infusion 
(Cycle 1 only)X
2 24 ±[ADDRESS_418094] -end of 
infusion (Cycle 1 only)X X X X
3 Anytime during day (Cycle 1 
only)X
8±[ADDRESS_418095] end of infusion 
(Cycle 1 only)X
[ADDRESS_418096] end of infusion 
(Cycle 1 only)X
[ADDRESS_418097] end of infusion 
(Cycle 1 only)X
22±2 Anytime during day (Cycle 1 
only)X
3-6 1 Predose X X X X
1 End of infusion X
Follow -
upsOccurs on the day the follow -
upsoccur.X X X
Abbreviations:  ECD = extracellular domain; EGFR = epi[INVESTIGATOR_3506]; MET = mesenchymal -
epi[INVESTIGATOR_43920]; PK =pharmacokinetic; V = volume of distribution .
aSamples are requested to be taken immediately before the dose and imme diately after the end of the LY3164530 
infusion .  Aberrations to specified sampling times will not be considered protocol deviations as long as the 
samples are taken and the actual sampling time is recorded .  It is essential that the actual times of LY3164530 
dose and samples are recorded accurately on the appropriate forms .
I7H-MC-JNBA (b) Phase [ADDRESS_418098] end of 
infusion X
2 24 ±[ADDRESS_418099] end of 
infusion (Cycle 1 only)X
[ADDRESS_418100] end of 
infusion (Cycle 1 only)X
[ADDRESS_418101] end of 
infusion (Cycle 1 only)X
23 24 ±[ADDRESS_418102] -end of 
infusion (Cycle 1 only)X
24 Anytime during day  
(Cycle 1 only)X
3-6 1 Predose X X X X
1 End of infusion X
Follow -up Occurs on the day the 
follow -ups occur.X X X
Abbreviations:  ECD = extracellular domain; EGFR = epi[INVESTIGATOR_3506]; MET = mesenchymal-
epi[INVESTIGATOR_43920]; PK =pharmacokinetic; V = volume of distribution .
aSamples are requested to be taken immediately before the dose and imme diately after the end of the LY3164530 
infusion.  Aberrations to specified sampling times will not be considered protocol deviations as long as the 
samples are taken and the actual sampling time is recorded.  It is essential that the actual times of LY3164 530 
dose and samples are recorded accurately on the appropriate forms .
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 68
LY3164530Protocol JNBA  ECG, Chemistry ,and Attachment 4.
Hematology  Collection Schedule
Schedule 1
Cycle Day Collection Time Central 
Triplicate ECGCentral 
Single ECGLocal 
HematologyLocal 
Chemistry
Screening X X X
1 1 Predose X X X
1 EOI (+ 10 min) X XaXa
1 2 ±0.25 hours EOI X
1 6 ±0.25 hours EOI X
2 24 ±4 hours EOI X XaXa
3 48 ±4 hours EOI X XaXa
8 X X X
15 Predose X X X
15 EOI (+ 10 min) X
15 2 ±0.25 hours EOI X
15 6 ±0.25 hours EOI X
22 X X X
2 1 Predose X X X
8 X X X
15 Predose X X X
22 X X X
3-X 1 Predose X X X
15 Predose X X X
Follow up 28 X X X
Abbreviations:  ECG = electrocardiogram; EOI = end of infusion; min = minute.
a If an abnormality in hematology or chemistry is consistently observed in the [ADDRESS_418103] -infusion laboratory samples (EOI, and 24 hours and 48 hours after EOI) must be 
repeate d for subsequent infusions until they are normal or return to baseline levels.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 69
LY3164530Schedule 2
Cycle Day Collection Time Central 
Triplicate ECGCentral 
Single ECGLocal 
HematologyLocal 
Chemistry
Screening X X X
1 1 Predose X X X
1 EOI (+ 10 min) X XaXa
1 2 ±0.25 hours EOI X
1 6 ±0.25 hours EOI X
2 24 ±4 hours EOI X XaXa
3 48 ±4 hours EOI X XaXa
8 Predose X X X
8 EOI (+ 10 min) X
8 2 ±0.25 hours EOI X
8 6 ±0.25 hours EOI X
15 Predose X X X
22 Predose X X X
2-X 1 Predose X X X
8 Predose X XbXb
15 Predose X X X
22 Predose X XbXb
Follow up 28 X X X
Abbreviations:  ECG = electrocardiogram; EOI = end of infusion; min = minute.
a If an abnormality in hematology or chemistry is consistently observed in the [ADDRESS_418104] -infusion laboratory samples (EOI, and 24 hours and 48 hours after EOI) must be 
repeated for subsequent infusions until they are normal or return to baseline levels.
bIn Cy cle 2-X, if clinically significant changes are observed, hematology and/or chemistry should be obtained at 
least weekly until no longer clinically significant.  Otherwise these samples are not required.
I7H-MC-JNBA (b) Phase [ADDRESS_418105]
GGT Anti -smooth muscle antibody a
CPK 
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma glutamyl transferase; Ig = immunoglobulin; INR = International Normalised Ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 71
LY3164530Protocol JNBA  Recommendations for Attachment 6.
Reporting Serious Adverse Events
Recommendations for Reporting Serious Adverse Events
When contact[CONTACT_338297] a serious adverse event ( SAE ), please have the fo llowing 
inform ation available:
Patient Demographics
patient identificat ion (number), sex, date of birth, origin, height, and weight
Study Identification
full trial protocol number, invest igator's name, investigator’s number
Study Drug
drug code or drug name, unit dose, total daily dose, frequency, route, start d ose, 
cycle details, start date and last dose date (if applicable)
Adverse Event
descri ption, date of onset, severit y, treatm ent (including hospi[INVESTIGATOR_3094]), acti on 
taken wi th respect to study  drug, clinical significance, test and procedure results 
(if applicable)
Relationship to Study Drug & Protocol Procedures
Concomitant Drug Therapy
indicat ion, total  daily dose, duration of treatment, start date, action taken
In Case of Death
cause, autopsy  finding (if available), date, relat ionship to study  drug and protocol 
procedures.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 72
LY3164530Protocol JNBA mTPI [INVESTIGATOR_338261] 7.
The modified toxicit y probabili ty interval  (mTPI )method employs a simple beta -binomial 
hierarchical model .  Decisio n rules are based on calculat ing the unit probabilit y mass (UPM) of 3 
intervals corresponding to underdosing, proper dosing, and overdosing in terms of toxicit y.  
Specifically , the underdosing interval is defined as (0, p T-ε1), the overdosing interval as (p T+ε2, 
1), and the proper dosing interval as (p T-ε1, pT+ε2), where ε1and ε2are sm all fractions, such as 
0.05, to account for the uncertaint y around the true target toxicit y.  A sensit ivity analysis 
reported by  [CONTACT_79351] . (2010) showed that the mTPI [INVESTIGATOR_338262] ε values. 
In addi tion, ε1 and ε2 could take different values to reflect physician preference and the nature of 
the disease .  For advanced diseases wit h few treatment options, higher toxicit y rates might be 
considered acceptable, implying a specificat ion of ε2>ε1.  
For l essadvanced diseases, the 2 ε
values could be identical or ε1 could be > ε2.  The 3 dosing intervals are associated with 3 
different dose -escalat ion decisio ns.  
The under -dosing interval corresponds to a dose escalat ion 
(E), overdosing corresponds to a dose de escalat ion (D), and proper dosing corresponds to staying 
at the current dose (S). 
Given an interval and a probabilit y distribution, the UPM of that interval is defined as the 
probabilit y of the interval divided by [CONTACT_91036] .  The m TPI [INVESTIGATOR_338263], and the one wit h the l argest UPM implies the corresponding 
dose-finding decisio n.  That decisio n provi des the dose l evel to be used for future patients .  For 
example, if the underdosing interval has the largest UPM, decision E, to escalate, will be 
executed, and the next cohort of patients will be treated at the next -
higher dose level .  Ji et al .
(2010) show that the decision based on the UPM is optimal in that it minimizes a subsequent 
expected loss .  Under the mTPI [CONTACT_8345], a trial is terminated when eit her the l owest dose i s above 
the maximum tolerated dose ( MTD )or a pre -specified maximum sample size is reached.
Simulation
Asmall  simulati on study  was conducted to compare the mTPI [CONTACT_4490] 3+3 in ident ifying the right 
MTD .  Sixscenari oswere r un, each wi th 1000 simul ated tri als.  As in Study  JNBA, theMTD
hasa target toxicit y probabili ty of  PT=0.3 and ε1andε2 are set at 0.013 and 0.001 respectively .  
The scenarios assumed the true probabilit ies of six doses as fo llows:  scenario 1= (0.1, 0.2, 0.3, 
0.4, 0.5, 0.6) ;scenario 2= (0.08,
0.16, 0.24, 0.3,0.38, 0.46) ;scenario 3= (0.04, 0.08, 0.12, 0.16,
0.2, 0.24 );scenario 4= (0.4, 0.5, 0.6, 0.7, 0.8, 0.9);scenario 5= (0.04, 0.08, 0.12, 0.16, 0.2, 0.58 );
and scenario 6= (0.06, 0.46, 0.53, 0.6,0.67, 0.74).  For all scenari os, the probabilit y ofselect ing 
each dose was summarized , the average number of pat ients treated at each dose and average 
number of patients experience DLT at each dose .  The simulat ion demo nstrates that ,in general ,
mTPI m ethod correctly  identifies the MTD more than 3+3 and appears to be as safeas3+3 
method in that it puts a similar percentage of patients on t oxic doses .
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 73
LY3164530ScenarioDose True Selection Prob (%) # of Subjects Treated # of Toxicities
Level Prob (tox) mTPI 3+3 mTPI 3+3 mTPI 3[PHONE_7031] 5.8 24.4 3.53 4.42 0.38 0.44
2 0.2 20.8 30.3 6.89 4.55 1.45 0.89
3 0.3 35.1 19.4 8.21 3.43 2.39 1
4 0.4 28.4 4.4 6.94 1.61 2.78 0.68
5 0.5 7.2 0.5 2.99 0.43 1.54 0.22
6 0.6 1.3 0 1.06 0.06 0.62 0.04
21 0.08 3.4 20.8 2.67 4.15 0.22 0.31
2 0.16 13.2 26.4 5.17 4.49 0.83 0.75
3 0.24 20.6 19.5 5.81 3.69 1.38 0.91
4 0.3 29.2 10.8 7.29 2.32 2.22 0.67
5 0.38 23.7 2.8 5.48 1.1 2.09 0.42
6 0.46 9.5 1.6 3.48 0.36 1.63 0.17
31 0.04 0.8 7.3 1.6 3.52 0.07 0.14
2 0.08 1.7 12.1 2.07 3.88 0.15 0.33
3 0.12 3.6 18.3 2.73 3.91 0.34 0.48
4 0.16 8.5 16.2 3.54 3.63 0.53 0.62
5 0.2 14.5 11.4 4.65 2.77 0.94 0.58
6 0.24 70.8 25.4 15.38 1.74 3.62 0.41
41 0.4 43.3 15.6 13.7 4.94 5.4 1.97
2 0.5 10.5 1.5 5.25 1.34 2.63 0.69
3 0.6 1.2 0 1.67 0.19 1 0.11
4 0.7 0 0.1 0.44 0.01 0.3 0
5 0.8 0 0 0.1 0.01 0.07 0.01
6 0.9 0 0 0.02 0 0.02 0
51 0.04 0.8 5.9 1.48 3.49 0.05 0.14
2 0.08 2.1 13.2 2.22 3.89 0.17 0.31
3 0.12 4 16.8 2.85 3.95 0.35 0.51
4 0.16 9.8 18.7 3.86 3.68 0.64 0.61
5 0.2 75.7 24.6 14.12 3.37 2.86 0.67
6 0.58 7.3 3.7 5.38 1.61 3.17 0.94
61 0.06 60.4 76.8 14.01 5.62 0.81 0.33
2 0.46 31.2 8.5 10.5 4.43 4.83 2.07
3 0.53 7.1 0.8 3.64 0.87 1.91 0.47
4 0.6 0.8 0 1.21 0.09 0.73 0.05
5 0.67 0 0.1 0.39 0.01 0.27 0
6 0.74 0 0.1 0.11 0.01 0.08 0
Abbreviation:  mTPI = modified toxicity probability interval.
Ji Y, Li u P, Li  Y, Bekel e BN. A m odified toxi city probabilit y interval  method for dose -finding 
trials. Clin Trials . 2010;7(6):653 -663.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 74
LY3164530Protocol JNBA  Protocol I7-MC-JNBA (b) Attachment 8.
Amendment Summary  A Phase 1 Study  of LY3164530, a 
Bispecific A ntibody  Targeting MET and EGFR, in Patients 
with A dvanced or Metastatic Cancer
Overview
Protocol  I7-MC-JNBA, A Phase 1 Study  of LY3164530, a Bi specific Ant ibody  Targeting MET 
and EGFR, in Pat ients with Advanced or Metastatic Cancer has been amended .  The new 
protocol  is indicated by  [CONTACT_11827] ( b) and will be used to conduct the study  in place of any 
preceding versio n of the protocol.
Introduction of a new weekly schedule for dosing.
Minor changes were made to increase the clarit y and consistency  of the 
docum ent andto correct ty pographical erro rs.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 75
LY3164530Revised Protocol Sections
Note: All deletions have b een i dentified by [CONTACT_58001] .
All additions have been ident ified by [CONTACT_58002] .
4.0 Abbreviat ions and Definit ions
AUC area under the serum plasma concentration -time curve
AUC (0-tlast) area under the serum plasma concentration -time curve from time zero to last 
measurable plasma concentration
AUC (0-∞) area under the serum plasma concentration -time curve from time zero to infinity
AUC 0-τ area under the serum versus time concentration-time curve over the dosing int erval
Cav,τ average serum concentration over the dosing interval
Cmax maximum serum plasma concentration
Cmin,τ minimum serum concentration over the dosing interval
EC50 the half maximal effective serum concentration
Q2W once ever y [ADDRESS_418106] ion and In Vitro/In Vivo Activit y
LY3164530 has high affinit y for both MET and EGFR and binds both receptors simultaneously 
in tum or cells.  As described in the Invest igator’s Brochure (Section 5.2.2), binding of 
LY3164530 to MET and EGFR blocks act ivation of both receptors by  [CONTACT_338298].  
In addit ion to i ts ligand -blocking act ivity, LY3164530 al so leads to internalizat ion and 
degradation of both receptors in tumor cells.  The abilit y of LY3164530 to internalize both 
receptors i s superior to the combinat ion of the [ADDRESS_418107] a 
panel of tumor cell lines.  In vivo, administration of LY3164530 results in dose -dependent 
antitumor activit y in cell line -derived non -small cell lung cancer, gastric cancer , and squamous 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 76
LY3164530cell cancer of the head and neck (SCCHN) xenografts, as well as in colorectal cancer and 
SCCHN patient -derived xenografts.  
5.5 Rational for Amendment (b)
As of [ADDRESS_418108] been treated in Study  JNBA at doses of 300, 600, 1000, and 
1250 mg on Days 1 and 15 of a 28 day  cycle.  One DLT (Cy cle 1) has been reported in a patient 
at the [ADDRESS_418109] m et the cri teria for 
a DLT had they  occurred in Cycle 1 (DLT -equivalent toxicit y).  These events included Grade [ADDRESS_418110] ions [maculo -papul ar rash, derm atitis acneiform, skin 
fissures, rash, skin exfo liation,and/or pustul ar rash] (n=14, 93.3%), hy pomagnesaemia (n=7, 
46.7%), and parony chia (n=4, 26.7%).  The following drug -related events occurred in 2 patients 
each (13.3%):  decreased appetite, dysgeuesia, fat igue, and hypokalaemia.  One SAE 
(hypo magnesaemia) was considered to be related to LY3164530 b y the invest igator and the 
Sponsor.  The event occurred in a metastatic cutaneous squamous cell carcino ma pat ient who 
had Grade [ADDRESS_418111] 1 dose of LY3164530 administered as a 1 or 2 -hour infusio n once every 2 
weeks (Q2W) across the dose range of 300 -1250 mg.  Dose -dependent increases in the systemic 
exposure (AUC, C max) ofLY3164530 fo llowing single and m ultiple doses were observed.  A 
minor am ount of accumulat ion in serum was observed wit hin Cycle 1 and between Cycles 1 and 
2 of treatment after 1000 mg Q2W (mean accumulation ratio of 1.1 within and between cycles).  
The LY3164530 systemic clearance (CL) decreased by  [CONTACT_3450]  2-fold on average when 
the dose was escalated fro m 600 m g to 1000 m g, indicat ing the saturation of cell -surface 
receptors by  [CONTACT_36940]3164530 and a slower non -receptor -mediated cl earance predominat ing at doses 
>600 m g.  While a more rapid receptor -mediated clearance (ie, target mediated drug disposit ion 
[TMDD]) predominates at low doses (ie, ≤600 m g).  In addi tion, the LY3164530 exposure 
following 1000 m g Q2W appears to be in an exposure range expected to achieve bio logical  
effects based on the nonclinical MKN45 xenograft PK/PD model est imates for the MET and 
EGFR half maximal effect ive serum concentrations ( EC 50) values.  The LY3164530 maximum 
serum  concentration (C max) after 1000 mg in Cycles 1 and 2 is greater (mean C max range: 295 -394 
µg/m L) than both the MET EC 50 (79.5 µg/mL; 0.4 µM) and EGFR EC 50(7.95 µg/mL; 0.04 µM) 
concentrations.  The average LY3164530 serum concentration over the dosing interval (C av,τ) 
during Cycl es 1 and 2 is also greater (mean C av,τrange: 102 -132 µg/mL) than the MET EC 50 and 
EGFR EC 50.  However, the minimum serum concentration over the dosing interval (C min,τ) of 
LY3164530 fo llowing 1000 mg in Cycles 1 and 2 (mean C min,τrange: 19 -49 µg/m L) is lower 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 77
LY3164530than the MET EC 50(79.5 ug/mL), which is the desired concentration to maintain throughout the 
dosing interval in order to maximize the bio logical activi ty of LY3164530.  
At a dose of 1000 mg, the mean terminal eliminat ion-life (t 1/2) is approximatel y 100 hours 
(approximately 4 days).  As a result, the administration of LY3164530 every 2 weeks may not be 
the optimal schedule of administration in order to achieve a LY3164530 C min,τnear the MET 
EC 50.  Therefore, it is hypothesized that weekly dosing of LY3164530 (i e, Days 1, 8, 15, and 22 
of a 28 day  cycle) will minimize the fluctuation between the peak (C max) and trough (C min,τ) 
serum  concentrati ons of LY3164530 leading to a more consistent inhibit ion of both MET and 
EGFR over the dosing interval (wit hminimal impact on the accumulat ion of LY3164530) and 
potenti ally greater pharm acologic activit y (PD response).  The MTD of LY3164530 when 
administered on Days 1 and 15 of a 28 day  cycle is 1000 m g.  As a resul t, the starting dose for 
the weekly schedule w ill be 500 mg.  The safet y, toxicity, PK, and PD associ ated wi th a weekly 
schedule will be assessed .  
6.2 Summary  of Study  Design
Study  JNBA is a mult icenter, nonrando mized, open label, dose escalat ion Phase 1 study  of IV 
LY3164530 in patients with advanc ed and/or metastatic cancer.  Eligible pat ients will receive 
LY3164530 as an infusio n on Days 1 and 15 ( Schedul e 1) or on Day s 1, 8, 15, and 22 (Schedule 
2)of each cycle.  A cy cle will  consist of 28 days and the schedules will enro ll in parallel .  
Dose escalat ion will be driven by  a modified toxi city probabilit y interval  (mTPI) m ethod.  The 
RP2D and schedule will be determined once at l east 10 pati ents, but no m ore than 20, are tr eated 
at a dose and schedule that is at or bel ow the m aximum  tolerated do se (MTD ).  The actual 
sample size for Study  JNBA is ant icipated to be approximately  50 pati ents depend ingson the 
incidence of DLTs and is ant icipated to be approximately 50 patients .
…
7.2.1 Dosing Schedule
For doses less than <[ADDRESS_418112] 
sites to extend the infusio n time for up to 3 hours for doses > ≥1000 mg.  
LY3164530 will be administered on Day s 1 and 15 every  28days (Schedule 1) or on Days 1, 8, 
15, and 22 every  28 days (Schedule 2).  The assigned dose, schedule, and duration o f infusio n of 

I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 78
LY3164530LY3164530 will be provided by [CONTACT_17190] a patient registration form.  A patient will be 
assigned to either Schedule 1 or Schedule 2 and will be maintained on that schedule for the 
durati on of  therapy .  Subsequent doses and/or infusion t imes should be adjusted as described in 
Secti on 7.2.5.
[IP_ADDRESS] Dose Escal ation Method 
…
Figure JNBA .1. Dose -finding spreadsheet of the modified toxicity probability 
interval method showing number of patients treated at a given 
dose vs. number of DLTs observed at that dose .
The beginning dose level for Schedule 1 was will be 300 m g.  The starting dose leve l for 
Schedule 2 will be 500 mg.  The dose will be escalated by a maximum increment of 100%.  If 
the beginning dose level is determined to be unacceptably toxic, a -[ADDRESS_418113] increment will be determined by [CONTACT_941] i nvesti gators and Lilly CRP/CRS, and may be 
less than the maximum increment allowed in the protocol.  Safet y data will be the primary  
criteria for both the decisio n to dose -escalate and for select ing the dose to be administered in the 
next cohort.  In addit ion, if avai lable at the time of the dose escalat ion decisio n, PK (maximum  
plasma serum  concentrati on [C max], area under the plasma serum  concentrati on-time curve 
[AUC], and CL) and/or PD results will be used as secondary/supporting data for dose escalation.  
No dose escalat ion can occur without prior discussio n and agreement between the invest igator 

I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 79
LY3164530and the Lilly CRP or CRS; the deci sion will be docum ented in wri ting.  I ntrapatient dose 
escalat ions are not permitted.
Although an example escalat ion table is shown in Table JNBA.3 , alternate doses m ay be 
selected.
Table JNBA. 3. Sample Dose Escal ation Schema
Dose Level
(Cohort)Schedule [ADDRESS_418114] pati ent is requi red to com plete a full cycle (28 day s) 
before subsequent patients can be dosed.  Subsequent patients in Cohort 1 can be dosed 
concurrent ly.  Beginning wit h Cohort 2 for Schedule 1 ,and for all cohorts wi th Schedule 2,
patients wi thin a cohort can be dosed concurrently.  
…
[IP_ADDRESS] Infusio n-Related Reactions
Due to the risk of hypersensit ivity react ions wi th any biological  agents, all  patients should 
continue to be closely mo nitored for si gns and symptom s indicat ive of an infusio n-related 
reacti on both in the acute period (immediately  or wi thin 24 hours after dosing) and up to several 
days to a few weeks after dosing for delayed react ions.  In Cycles [ADDRESS_418115] igator.   Monitoring should be 
performed in an area where resuscitat ion equipment and other agents (eg, epi[INVESTIGATOR_238], 
corticosteroi ds) are readily  available.  
…
[IP_ADDRESS] Skin Rash Reacti ons
Skin rash is a known toxicit y of EGFR inhibitors, and skin effects were observed with 
LY3164530 in a [ADDRESS_418116] of 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 80
LY3164530care premedicat ion for EGFR inhibitors, such as dexamethasone and/or topi[INVESTIGATOR_199]/or oral 
antibiotics, may be administered for the init ial and subsequent doses.  
If skin rash is ident ified as a DLT, prophylaxis may be permitted for the Cycle 1 Day 1 dose.  
Since LY3164530 is a bispecific ant ibody  with a fixed stoi chiometry for EGFR/MET, in the case 
of skin rash -only DLT, prophylaxis may be explored to maxim ize the chances o f effect ive 
combined MET/EGFR.  This decisio n will  be made fo llowing discussio ns wit h the invest igators 
and the Lilly CRP/CRS and will be documented in writ ing.  The dose escalat ion rules in Figure 
JNBA.1 would be fo llowed if this change i s implemented.
…
[IP_ADDRESS] Dose Delays and Omissio ns
The fo llowing rul es shoul d guide dosing:
Before each dose cycleof LY3164530 the following parameters are required:
Hem atologic:  ANC >1.5x 10 9/L, pl atelets >75 x 10 9/L, and hemogl obin >8g/dL.
Non-hematol ogic:  AEs m ustresolve to CTCAE v 4.03 Grade <1, or baseline.  
Except ions will be made for:  alopecia, fat igue, skin reactions , or other toxi cities that 
can be controlled wit h standard treatment; th ese toxicit ies must resolve to <Grade 2.
The start of a cy cle is the date of the Day  1 dose.  
For Schedule 1:   If the Day  15 dose cannot be administered within 21 days of the prior 
dose (by  [CONTACT_2006]  22), i t shoul d be omi tted.  The interval between LY3164530 doses must not 
be less than 14 days.  If a dose is delayed (for toxicit y or other ci rcumstances), the next 
dose should be adjusted so that there is at least a 14- day interval.
For Schedule 2:  If a dose cannot be administered within [ADDRESS_418117] not be less than 7 days.  
If a dose i s delayed (for toxicit y or other ci rcumstances), the next dose should be adjusted 
so that there is at least a [ADDRESS_418118] not be less than 14 days.  If a dose i s 
delayed (for toxi city or other ci rcumstances), the next dose should be adjusted so that 
there is at least a 14 -day interval .
If a dose cannot be administered within 28 days of the prior dose due to an AE, the patient 
shoul d be rem oved from  study drug treatment and should complete subsequent fo llow-up ( Table 
JNBA.4) .  
If the patient has completed the init ial on -study radiographic assessment (eg, at the end of 
Cycle 2) is in Cycle [ADDRESS_418119] igator and Sponsor.  
For instance, if a patient has a non–drug -related AE such as prolonged flu, the patient may 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 81
LY3164530continue on therapy  if, in the opi[INVESTIGATOR_3078] n of the investigator, he/she is showing benefit from 
therapy  and has recovered sufficient ly from the AE.  
A delay  of no m ore than 7 days because of ho lidays, weekends, inclement weather, or other 
justifiable events will be per mitted and will not be counted as a protocol deviat ion.  
[IP_ADDRESS] Dose Adjustments 
Dose adjust ments should fo llow the gui dance in Table JNBA.[ADDRESS_418120] be maintained at a reduced dose level for all remaining cycles.
I7H-MC-JNBA (b) Phase [ADDRESS_418121] occurrence  Decrease the LY3164530 infusion rate by 50% and monitor closely for any 
worsening.  For subsequent infusions, premedicate with diphenhydramine 
hydrochloride; additional premedication may be administered at the investigator’s 
discretio n.  
Grade [ADDRESS_418122] o ccurrence Stop LY3164530 infusion.  Administer diphenhydramine hydrochloride and 
acetaminophen for fever and oxygen.  Resume infusion at 50% of previous rate 
once infusion -related reaction has resolved or decreased to Grade 1 in severity, 
and monitor clos ely for any  worsening.  
For subsequent infusions, premedicate with diphenhydramine hydrochloride; 
additional premedication may be administered at the investigator’s discretion.  
The reduced rate should be used for all subsequent infusions.
Grade 1 or 2
Second occurrenceAdminister dexamethasone. 
For subsequent infusions, premedicate with diphenhydramine hydrochloride, 
acetaminophen, and dexamethasone.  The reduced infusion rate should be used 
for all subsequent infusions.
≥Grade [ADDRESS_418123] infusion tubing from the 
patient.  
Administer diphenhydramine hydrochloride, dexamethasone, bronchodilators for 
bronchospasm, and other medications/treatment as medically indicated.
Patients must not rece ive any  further LY3164530 treatment.
Skin 
reactions 
(eg, acne -
like rash)Grade [ADDRESS_418124] occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 following the rules in 
Section [IP_ADDRESS] .  Treatment with topi[INVESTIGATOR_199]/or oral antibiotics may should be 
considered. 
Grade 3
Second occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 following the rules in Section
[IP_ADDRESS] .  Dose reduce by 20% from assigned dose to the dose level used for the 
previous cohort for second occurrence.  Treatment with topi[INVESTIGATOR_199]/or oral 
antibiotics may should be considered.  
Grade [ADDRESS_418125] not receive any further LY3164530 treatment.
Other 
toxicities≥Grade [ADDRESS_418126] occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 or baseline following the 
rules in Section [IP_ADDRESS] .  Based on the investigator’s discretion, the full dose of 
LY3164530 may be administered or the dose may be reduced to the next lowest 
dose level.  If event recurs at sam e grade, then dose reduce LY3164530 to the 
next lowest dose.  
≥Grade 3
Second occurrenceDelay or omit LY3164530 treatment until ≤Grade 1 or baseline following the 
rules in Section [IP_ADDRESS] .  If event recurs at same grade, then dose reduce 
LY3164530 to the next lowest dose.  Exceptions may be made for transient 
changes in electrolytes that respond to treatment. 
Abbreviation:  CTCAE = Common Terminology Criteria for Adverse Events.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 83
LY3164530Note:  In addition, the dose may be reduced to the next lowest level for any toxicity at the discretion of the 
investigator.
7.3 Method of Assignment to Treatment
Patients who m eet all cri teria for enrollment will be assigned to receive LY3164530 in this study .  
Before each pat ient’s enro llment into the study, an eligibilit y check must be conducted between 
the invest igational site and the Lilly clinical  research personnel to confirm that each patient 
meets all enrollment criteria.  Upon confirmation of eligibilit y, the Sponsor will confirm the 
dose, schedule, infusion duration, and ident ificat ion number assignment for each patient.  
7.5 Concomitant Therapy
…
Patients shoul d receive full supportive care during the trial.  Routine prophylact ic use o f 
granulocy te col ony-stimulat ing factors (G -CSF) is not permitted during this study.  Should the 
use of hematopoiet ic co lony-stimulat ing factors (CSFs) be necessary , follow the American 
Society of Clinical  Oncol ogy (ASCO) recommendations for the use of CSFs (Smit h et al . 2006
2015 ).  
…
8.[ADDRESS_418127] igator’s Brochure.  This Phase 1 study contains safet y monitoring that will permit init ial 
characterizat ion of the safet y profile o f LY3164530 in pat ients with advanced or m etastatic 
cancer.  Study  procedures and their timing, including co llection of patient samples, are described 
in the Study  Schedule ( Attachment 1 ).
…
[IP_ADDRESS]. Pharmacodynamic Samples 
At the visit s and t imes specified in Attachment 3, serum and plasma samples will be co llected.  
The effect of LY3164530 on MET and EGFR pathway -specific targets m ay be expl ored to 
determine changes in potential bio markers such as circulat ing levels of the MET ligand HGF,  
EGFR ligands (eg, EGF, TGFalpha), MET/ECD, and EGFR/ECD.  The se samples m ay be used 
for expl oratory  research on new bio markers related to the MET/HGF and EGFR pathway.  In 
addition, expl oratory  samples to assess proteomic panel may  be collected.  A maximum of 3 
timepo ints may be remo ved per dosing schedule during th e study  if warranted and agreed upon 
between both the investigator and Lilly.
…
8.2.3.3Exploratory  Biomarker Blood Sam ples 
…
I7H-MC-JNBA (b) Phase [ADDRESS_418128] ive of the study  is to docum ent any ant itumor activit y.  Ref er to Attachment 1 
for details regarding the timing of specific efficacy measures.  
Each patient will be assessed by  [CONTACT_45332] m ore of the fo llowing radi ologic tests for tum or 
measurement:
Com puted tom ography  (CT) scan
Magnet ic resonance imaging (MRI)
Chest x -ray.
…
10.1 General Considerations
…
This is a Phase 1 study  with an open -label, dose escal ation design.  Patients will be enrolled into 
cohorts sequentially wit hout randomizat ion to dose level.  During dose escalation, the total 
sample size per cohort will be guide d by [CONTACT_941] m TPI [INVESTIGATOR_338256] (up to 20 patients per cohort before establishing the RP2D and schedule ).The total 
sample size is ant icipated to be approximately  [ADDRESS_418129] , AUC 0 -τ, and AUC 0-∞of 
LY3164530.  Other noncompartmental parameters, such as t 1/2, CL, volume of distribution (V), 
and accumulat ion rati os may be reported.   Addit ional exploratory  analyses will be performed if 
warranted by  [CONTACT_26739], and other validated PK software programs may be used if appropriate and 
approved by  [CONTACT_338299]/PD management.  The version of any  software used for the analysis 
will be docu mented and the program will meet the Lilly requirements of software validat ion.
Pharmacokinet icparameter estimates will be evaluated to delineate effects of dose 
proporti onali ty and tem poral  linearit y.  Log -transform ed C maxand AUC est imates will be 
asses sed to estimate ratios of geometric means and the corresponding 90% confidence intervals 
(CIs).
10.6 Pharmacodynamic Analyses
Provi ded that the data allows, PD and immunogenicit y data from  all patients m ay be analyzed 
using linear and/or nonlinear fixed and mixed effects models as appropriate.  Pharmacodynamic 
and immunogenicit y data will be summarized by [CONTACT_2715], drug concentration s, and t ime from dose 
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 85
LY3164530for each schedule of administration .  Potential  PD markers and immunogenicit y versus time data 
will be presented graphically for each patient and summarized by [CONTACT_338292] o f 
administration .  Abso lute and/or percent change from baseline for the PD markers may also be 
evaluated.  Data may be log- transformed prior to summarizing if necessary.  The interpatient and 
intrapat ient variability of the PD m arkers and immunogenicit y responses may also be assessed 
where appropriate.  Baseli ne m easurements m ay be evaluated as potenti al covari ates to assess 
their relationship to relevant PD responses.
10.7. Pharmacokinet ic/Pharmacodynamic Analyses
In addit ion to a standard noncompartmental assessment, and provided that the data allows, the 
LY3164530 serum concentrati on-time data may  be evaluated by  [CONTACT_338293]-based approaches as 
warranted.  Addit ional analyses, such as exposure -response modeling using the efficacy 
endpo ints, may also be explored.
Addit ional exploratory  analyses m ay be performed if w arranted by  [CONTACT_26739].
10.[ADDRESS_418130] been dosed at a given 
dose level for 1 cy cle of  treatm ent to eval uate the safet y and tol erabili ty of LY3164530.  The 
interim analysis may  include, but are not limited to, an assessment of available safet y, PK, and 
PD data.
Enrollment may cont inue during the interim analysis and the dose escalat ion rules as outlined in 
Figure JNBA.1 will cont inue to be fo llowed.
Addit ional interim analyses may be tri ggered and may include, but are not limited to, assessment 
of available safety , PK, and PD data.
12 References
…
Smith TJ, Bohl ke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo  G, Wade JL, Wozniak AJ, Armitage JO. 2015 
update of recommendat ions for the use of white blood cell growth factors: an evidence -based 
clinical practice guideline. J Clin Oncol . 2015. doi: 10.1200/JCO.2015.62.3488.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor 
SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pi[INVESTIGATOR_4607], Schiffer CA, Schwartzberg L, 
Somerfield MR, Som lo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update 
of recommendat ions for the use of white blood cell growth factors: an evidence -based clinical 
practi ce guideline. J Clin Oncol. 2006;24(19):3187 -3205.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 86
LY3164530Attachment 1 Protocol JNBA Study Sched ule
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 87Baseline Schedule
Study Period Baseline
Cycle BL
Visit0
Duration Up to 28 days
Relative Day to C1D1 ≤28 ≤14 ≤7
Procedure 
CategoryProcedureComments
Lab/
Diagnostic 
TestsLocal hematologyX
Local chemistryX
Local coagulationX
Local urinalysisX
Local pregnancy testX XMust be done [ADDRESS_418131] dose of study drug if patient is a woman 
of child -bearing potential .  May be urine or serum specimen.
Central  ECGXTriplicate ECG.  
Biopsy of pretreatment tumor tissueXUnless the Sponsor and investigator document that the biopsy may be omitted ; 
sample should be taken only after study eligibility is confirmed  
Archived tumor tissue (only if available)XOnly for those patients that meet inclusion/exclusion criteria
Tumor markers XOnly if appropriate for the tumor type of the patient.  
Exploratory biomarker blood sample for 
pharmacogenomicsXIf possible, this sample should be collected at the time on the same day as ofthe 
biopsy.
Immunogenicity sampleX
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 88During Treatment Study Schedule 
Study Period Study Treatment Period
Cycle/Visit 1 2 3-Xa
Duration 28 days 28 days 28 days
Relative Day 
within Dosing 
Cycle1 2 3 8 15 22 1 8 15 22 1 8 15 22
Procedure 
CategoryProcedure Comments
Physical 
ExaminationPhysical exam (including 
weight and skin inspections)X X X May be completed up to 7 days prior to the treatment 
infusion. 
Vital signs X X X X X X X X X X* X X* Includes blood pressure, pulse, and temperature.  For 
Cycles 1 -2,Aat a minimum, vital signs should be 
obtained prior to infusion , during infusion, and at 1 
hour EOI (Section [IP_ADDRESS] ). In Cycle 3 -X, vital signs 
should be taken predose and when clinically indicated.
* Only need to be collected for patients on Schedule 2
ECOG performance status X X X May be completed up to 7 days prior to the treatment 
infusion
Lab/
Diagnostic 
TestsLocal hematology X X X X X X X X X X X X On C1D1, both pre -dose and post -dose samples 
should be drawn.  See Attachment [ADDRESS_418132] -dose samples should be 
drawn.  See Attachment 4
Schedule 2:  In Cycle [ADDRESS_418133] -dose samples 
should be drawn.  See Attachment 4
Schedule 2:  In Cycle [ADDRESS_418134] an infusion -related reaction to 
LY3164530, all attempts should be made to obtain 
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 89immunogenicity sample as close to the onset of the 
event as possible, at the resolution of the event and 28 
days following the event.  A portion of the sample 
taken for immunogenicity testing may be used for PK 
analysis.
MET and EGFR ECD 
pharmacodynamic samplesX X X X X X See Attachment 3 .  
MET and EGFR ligands 
pharmacodynamic samples ,X X X X X X See Attachment 3 .
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 90During Treatment Study Schedule 
Study Period Study Treatment Period
Cycle/Visit 1 2 3-X
Duration 28 days 28 days 28 days
Relative Day 
within Dosing 
Cycle1 2 3 8 15 22 1 8 15 22 1 8 15 22
Procedure 
CategoryProcedure Comments
Lab/
Diagnostic 
Tests 
(cnt’d)Proteomic blood sample X X X X X X See Attachment [ADDRESS_418135] once.  Sample can be collected at any time if 
not collected on C1D1.
Exploratory biomarker blood 
sample for pharmacogenomicsX X Sample to be collected C7D1.
Central ECG X X X X X X X X X X X X* X X* In Cycle 1, triplicate ECGs collected predose, at EOI, 
2 hours EOI, and 6 hours EOI on the day of dosing .  
If possible, obtain prior to any associated blood 
draws.  In Cycles 2 -X, single ECGs should be 
obtained predose on the day of dosing. On non -dosing 
days,the ECG may be obtained at anytime, but if 
possible they should be obtained near to the  same 
time of day as the C1D1 ECG. See Attachment 4 .
*Schedule 2 only.  
Tumor markers X X If applicable to tumor type of the patient; may be 
drawn up to 3 days prior to the planned assessment.
Optional tumor biopsy X
Tumor 
AssessmentTumor measurement
(palpable or visible)X X Perform at least every [ADDRESS_418136] every 8 weeks other cycle (approximately every 
8 weeks )between D22 -28.  May be omitted if patient 
has clear signs of progressive disease.
Adverse Events Collection/CTCAE Grading X X X
Concomitant Medication Notation X X X
LY3164530 –Schedule 1 X X X X X X
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 91LY3164530 –Schedule [ADDRESS_418137] been on treatment for more 
than 1 year and are continuing to derive benefit from treatment.  This decision will be documented in writing.
LY3164530
I7H-MC-JNBA (b) Phase [ADDRESS_418138] dose of 
study therapy or, if study therapy has been omitted for an extended period, the 
date it is decided that the patient will not restart study therapy .
Duration28 5 days
Relative Day 28
Procedure 
CategoryProcedure Comments
Physical 
Examination Weight X
Vital signs X Includes blood pressure, pulse, and temperature.
ECOG performance status X
Tumor 
AssessmentTumor measurement (palpable or visible) XPerformed if lesion is assessed as target or non -target.  Not required if 
progressive disease is documented while on treatment.
Radiologic imaging according to RECIST XThe same method of imaging used at baseline should be used for each 
subsequent assessment.  Not required if progressive disease is documented while 
on treatment or if there are clear signs of clinical progression.  
Adverse Events Collection/CTCAE Grading XAfter Visit 801, only study protocol -or drug -related events are reported.  If a 
patient has an ongoing AE or SAE possibly related to LY3164530 (eg, abnormal 
electrolytes), the patient should be followed until the event is resolved, the event 
is no long er considered to be drug -related, the event becomes stable or returns to 
baseline, a new treatment is initiated for the patient, or the patient dies or is lost 
to follow -up.  Any subsequent follow -up(s) for AEs will be no more than 28 
days ±[ADDRESS_418139] abnormal electrolytes, as 
electrolyte depletion is known to occur for > 6 weeks after EGFR monoclonal 
antibody therapy.  
Central ECG X Single ECG.  
Tumor markers X If applicable to tumor type of the patient.
Optional tumor biopsy X From patients willing to consent.  
LY3164530
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 93Lab/
Diagnostic 
TestsExploratory biomarker blood sample X
PK sample X
Immunogenicity sample XIn addition to the scheduled sample, if a patient should have an infusion reaction 
to LY3164530, all attempts should be made to obtain immunogenicity sample as 
close to the onset of the event as possible, at the resolution of the event, and 30 
days following the event.
If a patient requires subsequent follow -ups (eg, for an ongoing AE), an 
immunogenicity sample should be obtained, if possible.  A portion of the sample 
taken for immunogenicity testing may be used for PK analysis .
MET and EGFR ECD pharmacodynamic 
samplesX
MET and EGFR ligand pharmacodynamic 
samplesX
Proteomic blood sample X Only if patient discontinues prior to Cycle 6.
Abbreviations:  AE = adverse event; BL = baseline; C = cycle; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; D = 
day; ECD = extracellular domain; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; EGFR = 
epi[INVESTIGATOR_3506]; EOI = end of infusion; HPV = human papi[INVESTIGATOR_28597]; MET = mesenchymal -epi[INVESTIGATOR_43920]; MRI = magnetic 
resonance imaging; PK =pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event.
I7H-MC-JNBA (b) Phase [ADDRESS_418140] end of infusion 
(Cycle 1 Oonly)X
2 24 ±[ADDRESS_418141] -end of 
infusion (Cycle 1 only)X X X X
3 Anytime during day  (Cycle 1 
only)X
8±[ADDRESS_418142] end of infusion 
(Cycle 1 only)X
[ADDRESS_418143] end of infusion 
(Cycle 1 only)X
[ADDRESS_418144] end of infusion 
(Cycle 1 Oonly)X
22±2 Anytime during day  (Cycle 1 
only)X
3-6 1 Predose X X X X
1 End of infusion X
Follow -
ups Occurs on the day the follow -
ups occur.X X X
Abbreviations:  ECD = extracellular domain; EGFR = epi[INVESTIGATOR_3506]; MET = mesenchymal-
epi[INVESTIGATOR_43920]; PK =pharmacokinetic; V = volume of distribution.
aSamples are requested to be taken immediately before the dose and immediately after the end of the LY3164530 
infusion.  Aberrations to specified sampling times will not be considered protocol deviations as long as the 
samples are taken and the actual sampling time is recorded.  It is essential that the actual times of LY3164530 
dose and samples are recorded accurately on the appropriate forms .
I7H-MC-JNBA (b) Phase [ADDRESS_418145] end of infusion X
2 24 ±[ADDRESS_418146] -end of 
infusion X X X X
3 Anytime during day X
8 Predose X X
8 End of infusion (Cycle 1 only) X X
15 Predose (Cycle 1 only) X X X
15 End of infusion (Cycle 1 only) X X
22 Predose(Cycle 1 only) X X X X
22 End of infusion (Cycle 1 only) X X X X
[ADDRESS_418147] end of infusion 
(Cycle 1 only)X
[ADDRESS_418148] end of infusion 
(Cycle 1 only)X
[ADDRESS_418149] end of infusion 
(Cycle 1 o nly)X
23 24 ±[ADDRESS_418150] -end of 
infusion (Cycle 1 only)X
24 Anytime during day  (Cycle 1 
only)X
3-6 1 Predose X X X X
1 End of infusion X
Follow -
ups Occurs on the day the follow -
ups occur.X X X
Abbreviations:  ECD = extracellular domain; EGFR = epi[INVESTIGATOR_3506]; MET = mesenchymal-
epi[INVESTIGATOR_43920]; PK =pharmacokinetic; V = volume of distribution .
aSamples are requested to be taken immediately before the dose and immediately after the end of the LY3164530 
infusion.  Aberrations to specified sampling times will not be considered protocol deviations as long as the 
samples are taken and the actual sampling time is recorded.  It is essential that the actual times of LY 3164530 
dose and samples are recorded accurately on the appropriate forms .
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 96
LY3164530Attachment 4 Protocol JNBA ECG, Chemistry, and Hematology Collection 
Schedule
Schedule 1
Cycle Day Collection Time Central 
Triplicate ECGCentral 
Single ECGLocal 
HematologyLocal 
Chemistry
Screening X X X
1 1 Predose X X X
1 EOI (+ 10 min) X XaXa
1 2 ±0.25 hours EOI X
1 6 ±0.25 hours EOI X
2 24 ±4 hours EOI X XaXa
3 48 ±4 hours EOI X XaXa
8 X X X
15 Predose X X X
15 EOI (+ 10 min) X
15 2 ±0.25 hours EOI X
15 6 ±0.25 hours EOI X
22 X X X
2 1 Predose X X X
8 X X X
15 Predose X X X
22 X X X
3-X 1 Predose X X X
15 Predose X X X
Follow up 28 X X X
Abbreviations:  ECG = electrocardiogram; EOI = end of infusion; min = minute.
a If an abnormality in hematology or chemistry is consistently observed in the [ADDRESS_418151] -infusion laboratory samples (EOI, and 24 hours and 48 hours after EOI) must be 
repeate d for subsequent infusions until they are normal or return to baseline levels.
I7H-MC-JNBA (b) Phase 1 Oncology Protocol Page 97
LY3164530Schedule 2
Cycle Day Collection Time Central 
Triplicate ECGCentral 
Single ECGLocal 
HematologyLocal 
Chemistry
Screening X X X
1 1 Predose X X X
1 EOI (+ 10 min) X XaXa
1 2 ±0.25 hours EOI X
1 6 ±0.25 hours EOI X
2 24 ±4 hours EOI X XaXa
3 48 ±4 hours EOI X XaXa
8 Predose X X X
8 EOI (+ 10 min) X
8 2 ±0.25 hours EOI X
8 6 ±0.25 hours EOI X
15 Predose X X X
22 Predose X X X
2-X 1 Predose X X X
8 Predose X Xb Xb
15 Predose X X X
22 Predose X Xb Xb
Follow up 28 X X X
Abbreviations:  ECG = electrocardiogram; EOI = end of infusion; min = minute.
a If an abnormality in hematology or chemistry is consistently observed in the [ADDRESS_418152] -infusion laboratory samples (EOI, and 24 hours and 48 hours after EOI) must be 
repeated for subsequent infusions until they are normal or return to baseline levels.
bIn Cy cle 2-X, if clinically significant changes are observed, hematology and/or chemistry should be obtained at 
least weekly until no longer clinically significant.  Otherwise these samples are not required.
[COMPANY_003]Leo Document ID = 5b2565df-ce44-4304-ba4b-959e67a3df66
Approver:
Approval Date & Time: 28-Sep-2015 17:31:23 GMT
Signature [CONTACT_32869]: Approved
Approver:
Approval Date & Time: 28-Sep-2015 21:59:40 GMT
Signature [CONTACT_32869]: Approved[COMPANY_003]